# Synopulse

> Biopharma and healthcare intelligence.


## Posts

- [Simplify Healthcare Captures 30% Medicare Advantage Market Share](https://synopulse.com/simplify-healthcare-captures-30-medicare-advantage-market-share/): Platform achieves 30% market dominance in Medicare Advantage bid submissions. 
- [Synopulse Weekly: Top Deals, FDA Moves & Pricing Insights](https://synopulse.com/synopulse-weekly-top-deals-fda-moves-pricing-insights/): Top biopharma deals, FDA approvals, and market access news from the past week.
- [Innovent's IBI363 Gains Second China BTD for Resistant Lung Cancer](https://synopulse.com/innovents-ibi363-gains-second-china-btd-for-resistant-lung-cancer/): Advertisement China’s National Medical Products Administration has granted a second Breakthrough Therapy Designation to Innovent Biologics’ IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for treating immunotherapy-resistant squamous non-small cell lung cancer (sqNSCLC). The designation applies to unresectable, locally advanced, or metastatic sqNSCLC that has progressed following anti-PD-(L)1 immunotherapy and platinum-based chemotherapy. This marks IBI363’s fourth regulatory recognition, adding to existing NMPA BTD and FDA Fast Track designations for both sqNSCLC and melanoma indications. The regulatory milestone follows encouraging Phase 1 data presented at the 2025 ASCO Annual Meeting, demonstrating manageable safety profiles and efficacy signals across multiple immunotherapy-resistant tumor types. ... Read more
- [NICE Endorses Linzagolix for NHS Endometriosis Care](https://synopulse.com/nice-endorses-linzagolix-for-nhs-endometriosis-care/): Advertisement The National Institute for Health and Care Excellence (NICE) has approved linzagolix combined with hormonal add-back therapy for endometriosis treatment within the NHS, expanding therapeutic options for an estimated 1.5 million women in the UK affected by this chronic condition. Clinical trials have substantiated that linzagolix effectively reduces both dysmenorrhea and non-menstrual pelvic pain in adult women of reproductive age suffering from endometriosis. The approval follows comprehensive clinical and economic evaluations demonstrating linzagolix’s non-inferiority to established treatments. The outcomes of these trials positioned linzagolix on par with existing treatments such as leuprorelin acetate, offering comparable pain relief and symptom management. ... Read more
- [CAT-os Tool Addresses Global Orthopedic Surgery Gap](https://synopulse.com/cat-os-tool-addresses-global-orthopedic-surgery-gap/): Advertisement A validated capacity assessment tool designed to strengthen orthopedic surgery capabilities in low- and middle-income countries (LMICs) has demonstrated excellent reliability and practical utility in pilot testing, addressing a critical healthcare disparity that affects millions globally. The Capacity Assessment Tool for Orthopedic Surgery (CAT-os) provides systematic evaluation frameworks for surgical outreach programs targeting regions where orthopedic surgeon availability stands at just 1 per million residents compared to 100 per million in high-income countries. The tool’s development addresses significant infrastructure gaps in global orthopedic care, where musculoskeletal injuries constitute a substantial proportion of worldwide disease, with access limited to many due ... Read more
- [Randox Gains FDA De Novo Clearance for Hemophilia CDx](https://synopulse.com/randox-gains-fda-de-novo-clearance-for-hemophilia-cdx/): Advertisement Randox Laboratories has secured FDA de novo clearance for its ConcizuTrace ELISA companion diagnostic, designed to quantify plasma concentrations of Novo Nordisk’s recently approved hemophilia treatment Alhemo (concizumab-mtci). The regulatory milestone comes just weeks after Alhemo received FDA approval in December 2024 as a once-daily prophylactic injection for adults and pediatric patients 12 years and older with hemophilia A or B with inhibitors. The ConcizuTrace ELISA is intended for quantitative measurement of concizumab-mtci concentration in human 3.2% citrated plasma samples from hemophilia A and B patients after 4 weeks from treatment initiation. This companion diagnostic addresses a critical therapeutic drug ... Read more
- [Medicare Expands Signatera Genome MRD Assay Coverage](https://synopulse.com/medicare-expands-signatera-genome-mrd-assay-coverage/): Advertisement Medicare has approved coverage for Natera’s genome-based Signatera molecular residual disease (MRD) assay under LCD L38779, extending access to beneficiaries across six cancer indications. The coverage applies to colorectal, breast, bladder, ovarian, and lung cancers, as well as pan-cancer immunotherapy monitoring, aligning with the scope of Natera’s original Signatera test. This regulatory milestone positions the genome-enhanced version as a Medicare-reimbursed standard of care option for post-treatment cancer surveillance. The coverage determination was anchored by robust evidence, leveraging over 100 published clinical studies validating Signatera, demonstrating Medicare’s confidence in the assay’s analytical validity. At the 2025 ASCO Annual Meeting, Natera presented ... Read more
- [CND's Syn-One Test Shows 75% Detection in Sleep Disorder](https://synopulse.com/cnds-syn-one-test-shows-75-detection-in-sleep-disorder/): Advertisement CND Life Sciences reported baseline results from its NIH-sponsored Syn-Sleep Study, demonstrating the Syn-One Test’s ability to detect phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (iRBD). The 24-month longitudinal study enrolled 80 participants across 11 US sites, representing a critical validation step for cutaneous biomarker detection in prodromal neurodegenerative disease. The study’s design addresses a significant diagnostic gap in synucleinopathy management. iRBD patients face a 73.5% risk of converting to Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy within 12 years, yet current diagnostic approaches rely on clinical manifestation rather than molecular ... Read more
- [Stryker Acquires Inari Medical: Strategic Expansion into Peripheral Vascular Treatment Market](https://synopulse.com/stryker-acquires-inari-medical-strategic-expansion-into-peripheral-vascular-treatment-market/): Advertisement Stryker Completes $3.1 Billion Acquisition of Inari Medical, Entering High-Growth Venous Thrombectomy Market Stryker Corporation (NYSE: SYK), a global leader in medical technology, has completed its acquisition of Inari Medical, Inc. (NASDAQ: NARI), a pioneering developer of devices for venous thromboembolism (VTE) treatment. This strategic $3.1 billion acquisition marks Stryker’s entry into the rapidly growing peripheral vascular segment, expanding its interventional medicine portfolio. Key Highlights of the Stryker-Inari Medical Acquisition Inari Medical: Revolutionizing Venous Clot Treatment Founded in 2013, Inari Medical has disrupted the venous care landscape with its purpose-built mechanical thrombectomy systems. Unlike competitors who adapted arterial devices for ... Read more
- [Bain Capital Acquires Mitsubishi Tanabe Pharma](https://synopulse.com/bain-capital-acquires-mitsubishi-tanabe-pharma/): Advertisement Bain Capital, a leading global private investment firm with approximately $160 billion in assets under management, has announced its agreement to acquire Mitsubishi Tanabe Pharma Corporation (MTPC), a renowned Japanese pharmaceutical company with over 300 years of heritage. This transaction represents one of Bain Capital’s largest investments in the pharmaceutical sector and demonstrates its continued strategic focus on healthcare as a key investment vertical. Key Highlights of Bain Capital’s Private Equity Investment in MTPC Investment Thesis: Why Mitsubishi Tanabe Pharma Attracted Bain Capital’s Attention As a private equity investor, Bain Capital identified MTPC as an attractive acquisition target based on ... Read more
- [Pure Health Acquires 60% Stake in Hellenic Health Care Group in $2.3 Billion Deal, Expanding Global Healthcare Reach](https://synopulse.com/pure-health-acquires-60-stake-in-hellenic-health-care-group-in-2-3-billion-deal-expanding-global-healthcare-reach/): Advertisement On Jan. 27, 2025, Pure Health has agreed to acquire a 60% stake in Hellenic Health Care Group (HHG). The transaction values. 2.3 billion at USD. Pure Health is the largest healthcare group in the Middle East. Hellenic Health Care Group is the largest private healthcare provider in Greece and Cyprus. Pure Health Partnering with CVC in Healthcare Investments CVC is a leading global private markets manager with approximately USD 201 billion in assets under management. Pure Health and CVC have collaborated to expand HHG into a larger organization. CVC’s funds are invested in approximately 130 companies worldwide, generating USD ... Read more
- [LifeScience Weekly Digest: Key Industry Updates (13th – 17th January) ](https://synopulse.com/lifescience-weekly-digest-key-industry-updates-13th-17th-january/): Advertisement JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with Whitecap Biosciences’ glaucoma and geographic atrophy studies. Lantheus Holdings expanded Alzheimer’s diagnostics with Neuraceq® after acquiring Life Molecular Imaging for $350 million. BioMérieux expanded its acute diagnostic capabilities with SpinChip’s rapid proof-of-concept platform. Innovative therapies, such as Eli Lilly’s Omvoh® for Crohn’s disease and AstraZeneca’s ... Read more
- [Eli Lilly Shakes Up JPM25 with $2.5B Scorpion Buyout in Breast Cancer Battle](https://synopulse.com/eli-lilly-shakes-up-jpm25-with-2-5b-scorpion-buyout-in-breast-cancer-battle/): Advertisement Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push in Breast Cancer Therapies Novartis entered the PI3Kα inhibitor space in 2019 with Piqray, followed by Roche’s Itovebi, which gained FDA approval late last year. The Scorpion deal now provides Lilly with a more advanced clinical-phase candidate, STX-478, fast-tracking its efforts to enter the race. ... Read more
- [Johnson & Johnson Steals the Spotlight at JPM Conference with $14.6B Intra-Cellular Therapies Acquisition](https://synopulse.com/johnson-johnson-steals-the-spotlight-at-jpm-conference-with-14-6b-intra-cellular-therapies-acquisition/): Advertisement On Monday, Johnson & Johnson (J&J) made headlines at the J.P. Morgan Healthcare Conference by announcing its agreement to acquire Intra-Cellular Therapies, a pioneering biotech company specializing in treatments for brain diseases. The deal, valued at $132 per share or approximately $14.6 billion, marks the largest biotechnology acquisition since early 2023. A Strategic Play in Neuroscience The crown jewel of this acquisition is Caplyta (lumateperone), a breakthrough medication approved in the U.S. for treating schizophrenia and bipolar depression. Intra-Cellular Therapies has also recently filed for FDA approval to expand Caplyta’s use to major depressive disorder (MDD), a condition that impacts ... Read more
- [GSK snaps up IDRx for up to $1.15B](https://synopulse.com/gsk-snaps-up-idrx-for-up-to-1-15b/): Advertisement Britan-based pharmaceutical giant GSK has agreed to acquire 100% of the outstanding equity interests (including all options and other incentive equity) in IDRx, a US-based, clinical-stage biopharmaceutical company focused on developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST). The acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) being developed as a first- and second-line therapy for GIST. The financial terms of the deal stipulate an upfront payment of $1 billion, with a further $150 million contingent on regulatory approval milestones. Additionally, GSK will be responsible for success-based milestone payments and tiered royalties owed to ... Read more
- [LifeScience Weekly Digest: Key Industry Updates (6th – 10th January) ](https://synopulse.com/lifescience-weekly-digest-key-industry-updates-6th-10th-january/): Advertisement In early 2025, significant developments across the biopharmaceutical and medical device sectors shaped the healthcare landscape. Stryker’s $4.9 billion acquisition of Inari Medical, Transcarent’s $621 million deal for Accolade, and several FDA designations for investigational treatments, such as Johnson & Johnson’s nipocalimab, highlight industry advancements. Medicare’s rescinding of coverage for certain cancer genetic tests and NICE’s recommendation of Lynparza reflect the growing role of genetic testing in cancer treatment. Meanwhile, China’s NMPA has approved therapies like Astellas’ VYLOY™ and Merck’s GARDASIL®. Medical device companies, including Roche and Johnson & Johnson MedTech, secured key regulatory approvals, while notable IP milestones were ... Read more
- [Regulatory Roundup: Weekly Insights on Pharma and MedTech—Key Updates from Leading Agencies (December 30th to January 3rd) ](https://synopulse.com/regulatory-roundup-weekly-insights-on-pharma-and-medtech-key-updates-from-leading-agencies-december-30th-to-january-3rd/): Advertisement Welcome to this week’s Regulatory Insights from Synopulse, featuring the latest updates from the FDA, EMA, and other global regulatory authorities. From groundbreaking drug approvals to critical recalls and new designations, we cover the most significant events driving the pharmaceutical sector. This comprehensive report offers a concise view of the regulatory milestones shaping the pharma, biotech, and MedTech industries, keeping you informed and ahead in a competitive landscape.  The United States Food and Drug Administration (FDA) The past year drew to a close when the thumbs-up from Bristol Myers Squibb came for OPDIVO  Qvantig (nivolumab + hyaluronidase-nvhy ). OPDIVO Qvantig ... Read more
- [Transcarent paying $621M to acquire health benefits navigator Accolade ](https://synopulse.com/transcarent-paying-621m-to-acquire-health-benefits-navigator-accolade/): Advertisement Transcarent has announced plans to acquire Accolade for $621 million, marking a significant step toward its mission of delivering affordable and high-quality healthcare solutions. The acquisition will combine Transcarent’s innovative WayFinding and care solutions with Accolade’s personalized healthcare platform, creating a unified and comprehensive healthcare experience for users.  This collaboration aims to enhance accessibility to healthcare, reduce costs, and streamline services for both employees and employers. The combined company will serve over 1,400 employer and payer clients, making it a major player in the healthcare navigation industry.  The integration is expected to drive better health outcomes by providing a seamless ... Read more
- [Pfizer picks Triana Biomedicines to find Molecular Glues for Cancer](https://synopulse.com/pfizer-picks-triana-biomedicines-to-find-molecular-glues-for-cancer/): Advertisement US pharmaceutical giant Pfizer announced a groundbreaking collaboration with Triana Biomedicines to develop Molecular Glue Degraders. The partnership aims to create multiple advanced therapies, including cancer. The collaboration is seen as a significant step forward in developing advanced medical treatments that can address challenging disease targets.  Targeted protein degradation is a novel and fast-growing segment. TPD is predicted to reach half a billion by the end of 2024, with a tremendous increase of seven billion by 2035, at a 32% CAGR.  TPD small molecules, sometimes known as degraders, use the body’s cellular machinery to degrade certain proteins that lead to ... Read more
- [OncoC4 merged with AcroImmune](https://synopulse.com/oncoc4-merginging-with-acroimmune/): Advertisement OncoC4, a biopharmaceutical firm in its final phases of developing advanced cancer therapies, is merging with AcroImmune, a developer of immunotherapies for malignant tumors and inflammatory diseases. The merger produces first- and best-in-class immunotherapies. Drs. Yang Liu and Pan Zheng co-founded OncoC4 and AcroImmune, and they share a common shareholder base. The combined firm was renamed OncoC4 Inc. with its corporate offices in Rockville, Maryland. The company merged in an all-stock deal, with Yang Liu as CEO. The combined business will have a broad pipeline of products and technologies. Furthermore, the company has expanded its R&D operations by creating additional ... Read more
- [CorroHealth Acquired Revenue Cycle Management Business from Navient](https://synopulse.com/corrohealth-acquired-revenue-cycle-management-business-from-navient/): Advertisement CorroHealth has finalized its acquisition of the healthcare revenue cycle management (RCM) business from Navient’s Xtend Healthcare, significantly expanding its capabilities in revenue cycle management consultancy and technology. This strategic move enhances CorroHealth’s RCM offerings, introducing multichannel patient engagement capabilities that were previously missing from its suite of services. By adding these capabilities, CorroHealth strengthens its position as a leader in providing comprehensive, end-to-end clinical and financial solutions to healthcare providers. The acquisition brings over 925 Xtend employees into the CorroHealth team, further boosting the company’s ability to deliver a more robust and well-rounded set of services. Pat Leonard, CEO ... Read more
- [NanoVation Therapeutics Partners with Novo Nordisk to Develop Genetic Medicines for Cardiometabolic and Rare Diseases](https://synopulse.com/nanovation-therapeutics-partners-with-novo-nordisk-to-develop-genetic-medicines-for-cardiometabolic-and-rare-diseases/): Advertisement Overview of the Deal:NanoVation Therapeutics has entered into a multi-year partnership with Novo Nordisk to develop cutting-edge genetic medicines that target cardiometabolic and rare diseases. Announced on September 18, 2024, this collaboration will leverage NanoVation’s long-circulating lipid nanoparticle (lcLNP™) technology, which enables RNA delivery to cells outside the liver, combined with Novo Nordisk’s expertise in developing therapies for cardiometabolic and rare genetic diseases. This partnership marks a significant step forward in the development of next-generation genetic medicines. NanoVation’s Technology and Collaboration Focus:NanoVation’s lcLNP™ technology is at the heart of this collaboration, addressing the challenges of conventional nucleic acid delivery systems ... Read more
- [Axcelead DDP and Eli Lilly Partner for Drug Discovery Programs](https://synopulse.com/axcelead-ddp-and-eli-lilly-partner-for-drug-discovery-programs/): Advertisement Deal OverviewAxcelead Drug Discovery Partners (Axcelead DDP), a Japanese drug discovery company, has entered into a strategic research and collaboration agreement with Eli Lilly and Company (Lilly), a global pharmaceutical leader. Announced on September 5, 2024, the collaboration aims to leverage Axcelead DDP’s innovative drug discovery technologies to support multiple drug discovery programs for Lilly. This partnership highlights Axcelead DDP’s growing reputation in the industry and its ability to develop new drug candidates through cutting-edge research. Axcelead’s capabilities and partnership focus:Axcelead DDP is recognized for its strong drug discovery capabilities, which include the use of artificial intelligence (AI) and other ... Read more
- [Organon Expands Dermatology Portfolio with Acquisition of Dermavant and Its VTAMA Cream](https://synopulse.com/organon-expands-dermatology-portfolio-with-acquisition-of-dermavant-and-its-vtama-cream/): Advertisement Organon, a global healthcare company dedicated to improving the health of women throughout their lives, has announced the acquisition of Dermavant Sciences Ltd., a dermatology-focused subsidiary of Roivant Sciences. This acquisition will broaden Organon’s dermatology capabilities in the U.S. and beyond. The move aligns with Organon’s long-term strategy of expanding into therapeutic areas with high unmet medical needs, particularly those affecting women. With the acquisition, Organon gains access to Dermavant’s lead product, VTAMA® (tapinarof) cream, a novel treatment for plaque psoriasis and potentially atopic dermatitis, pending FDA approval. Dermavant’s flagship product, VTAMA® cream, is a non-steroidal topical therapy approved by ... Read more
- [Kalsi Insurance Partners with Integrity to Provide Enhanced Insurance Solutions to Underserved Communities](https://synopulse.com/kalsi-insurance-partners-with-integrity-to-provide-enhanced-insurance-solutions-to-underserved-communities/): Advertisement Integrity Marketing Group has announced a partnership with Kalsi Insurance Agency to provide better life and health insurance options to underserved communities. Through this collaboration, Kalsi Insurance agents will gain access to Integrity’s cutting-edge technology platform, allowing them to better serve diverse populations such as immigrants and seniors by simplifying Medicare complexities. Kalsi Insurance, led by Navdeep Kalsi, places a high value on community involvement, particularly in serving immigrants and underserved populations who face difficulties navigating healthcare systems. Integrity’s partnership is consistent with Kalsi’s mission to provide personalized, accessible insurance solutions. Integrity’s technology will improve Kalsi Insurance’s efficiency, allowing for ... Read more
- [EQT to Acquire GeBBS Healthcare Solutions](https://synopulse.com/eqt-to-acquire-gebbs-healthcare-solutions/): Advertisement EQT Private Capital Asia has announced its agreement to acquire a controlling interest in GeBBS Healthcare Solutions from ChrysCapital. GeBBS specializes in revenue cycle management, health information management (HIM), and medical billing services, helping U.S.-based healthcare providers improve their financial performance through optimized revenue cycle processes and accurate coding and billing practices. Founded in 2005, GeBBS has a global presence with 13,000 employees across the U.S., India, the Dominican Republic, and the Philippines. The company has built strong relationships with a diverse customer base, including hospitals, physician groups, and other healthcare firms. EQT’s acquisition aims to support GeBBS in its ... Read more
- [A. Menarini Diagnostics and Nucleix Form Strategic Partnership for Non-Invasive Bladder Cancer Test in Europe](https://synopulse.com/a-menarini-diagnostics-and-nucleix-form-strategic-partnership-for-non-invasive-bladder-cancer-test-in-europe/): Advertisement A. Menarini Diagnostics and Nucleix have announced a strategic commercial agreement to exclusively market the Bladder EpiCheck® test in Europe. This non-invasive, CE-marked urine test is designed to detect and monitor bladder cancer and upper tract urothelial carcinoma (UTUC), providing an alternative to invasive cystoscopy. The partnership was revealed at the 36th European Congress of Pathology in Florence, where both companies highlighted the potential impact of the Bladder EpiCheck test. It is included in the European Association of Urology (EAU) Clinical Guidelines, supporting its use in both diagnosis and surveillance of non-muscle invasive bladder cancer (NMIBC) and UTUC. The test ... Read more
- [Stratipath And Roche Collaborate To Expand Access To Ai-powered Breast Cancer Diagnostics](https://synopulse.com/stratipath-and-roche-collaborate-to-expand-access-to-ai-powered-breast-cancer-diagnostics/): Advertisement Stratipath, a leader in AI-based precision diagnostic solutions, has announced a collaboration with Roche, the world’s largest biotechnology company and a global leader in in-vitro diagnostics. Through this partnership, Roche gains distribution rights to Stratipath’s AI-driven diagnostic tool, Stratipath Breast. This solution integrates seamlessly with Roche’s navify® Digital Pathology enterprise software, allowing users to perform AI-based prognostic risk profiling for breast cancer directly from the platform. Stratipath Breast is the first EU regulatory-compliant AI solution designed for breast cancer risk stratification. It uses deep learning to analyze digitized histopathology images, identifying patients at increased risk of disease progression. Unlike conventional ... Read more
- [Venteur Announces Strategic Partnership with United Benefit Advisors to Provide Personalized Insurance Solutions to Employers Nationwide](https://synopulse.com/venteur-announces-strategic-partnership-with-united-benefit-advisors-to-provide-personalized-insurance-solutions-to-employers-nationwide/): Advertisement Venteur, a healthcare startup focused on personalized health insurance for employees, has entered a strategic partnership with United Benefit Advisors® (UBA), the nation’s largest independent employee benefits advisory network. Through this collaboration, Venteur’s innovative Individual Coverage Health Reimbursement Arrangement (ICHRA) solutions will now be available to UBA member firms, helping them guide employers in offering tailored health insurance options to their workforce. Stacy Edgar, CEO and co-founder of Venteur, highlighted the importance of the partnership, stating, “This collaboration will enable employers across the country to leverage our services through trusted benefit advisors, advancing our mission to create a more affordable ... Read more
- [Valo Health, Merck KGaA Launch $3B+ AI Collaboration Targeting Parkinson’s Disease](https://synopulse.com/valo-health-merck-kgaa-launch-3b-collaboration-targeting-parkinsons-disease/): Valo Health has entered a collaboration with Merck KGaA, Darmstadt, Germany worth over $3 billion to accelerate AI-driven discovery of Parkinson’s disease therapies.
- [Minnesota Seeks $1B for Rural Health Transformation, but Medicaid Cuts Threaten Gains](https://synopulse.com/minnesota-seeks-1b-for-rural-health-transformation/): Minnesota applied for $1B under the federal Rural Health Transformation Program to strengthen rural hospitals, telehealth, and workforce capacity.
- [B. Braun to Pay $38.5M in DOJ Settlement Over Allegedly Faulty Knee Implant and False Claims](https://synopulse.com/b-braun-settled-with-over-faulty-knee-implant/): The DOJ has finalized a $38.5 million settlement with B. Braun’s Aesculap unit over allegations involving an early-failing knee implant that triggered false claims to Medicare and Medicaid.
- [Alkermes Raises Avadel Acquisition Offer to $2.37B, Outmaneuvering Lundbeck With Superior CVR Terms](https://synopulse.com/alkermes-raises-avadel-acquisition-offer-to-2-37b/): Alkermes has increased its offer to acquire Avadel to $22.50 per share, valuing the deal at up to $2.37 billion.
- [NeuroPulse Daily – Key Clinical, Discovery & Device Updates Across the Field](https://synopulse.com/neuropulse-daily-clinical-discovery-device-updates/): Today’s neurology roundup highlights momentum across Alzheimer’s and ALS drug development, spinal cord injury research, intravascular imaging, and next-gen MRI technologies.
- [Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair](https://synopulse.com/philips-debuts-deviceguide-to-enhance-real-time-navigation/): Philips Debuts AI DeviceGuide to Enhance Real-Time Navigation in Heart Valve Repair
- [IQWiG: No Added Benefit for Darolutamide Over Apalutamide Without Direct Comparative Data](https://synopulse.com/iqwig-no-added-benefit-for-darolutamide-vs-apalutamide/): IQWiG has concluded that darolutamide offers no proven added benefit over apalutamide for metastatic hormone-sensitive prostate cancer.
- [CMS Sets 2026 Medicare Premiums and Deductibles as Costs Rise and Policy Changes Take Effect](https://synopulse.com/cms-sets-2026-medicare-premiums-and-deductibles/): Advertisement CMS Sets 2026 Medicare Premiums and Deductibles as Cost Pressures Mount and Regulatory Fixes Temper Increases The Centers for Medicare & Medicaid Services (CMS) has released the 2026 Medicare Parts A and B premiums, deductibles, and income-related adjustment amounts, outlining another year of steady cost increases across the program. While the updates reflect predictable inflationary and utilization patterns, the 2026 notice carries added significance, it reveals the push-and-pull between rising care costs and targeted regulatory interventions that helped prevent even steeper premium spikes. Announced November 14, 2025, the updated premiums and deductibles will affect tens of millions of Medicare beneficiaries ... Read more
- [NICE Expands Cancer and Dermatology Options With Three Major Recommendations Across DLBCL, Myeloma, and Chronic Hand Eczema](https://synopulse.com/nice-expands-cancer-and-dermatology-options-with-three-major-recommendations-across-dlbcl-myeloma-and-chronic-hand-eczema/): NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.
- [Vietnam Targets 2026 Rollout of Free Annual Health Checks and Expanded Insurance Coverage](https://synopulse.com/vietnam-targets-2026-rollout-of-free-annual-health-checks-and-expanded-insurance-coverage/): Advertisement Doctors providing check-ups with a sign announcing free annual health checks and expanded insurance. Vietnam Sets Ambitious 2026 Plan for Free Annual Health Checks, Expanded Coverage, and System-Wide Reform Vietnam is preparing to deliver one of its most far-reaching public-health reforms in decades, a nationwide guarantee of one free annual health check or screening for every citizen starting in 2026. The proposal submitted to the National Assembly by Minister of Health Đào Hồng Lan marks a decisive shift toward preventive care as Vietnam works to modernize its health system and extend equitable access across its 100-million-plus population. The draft resolution ... Read more
- [Biogen’s High-Dose Nusinersen Wins CHMP Backing for Enhanced SMA Treatment](https://synopulse.com/biogens-high-dose-nusinersen-wins-chmp-backing/): Biogen has earned a positive CHMP opinion for its high-dose nusinersen regimen, supported by strong DEVOTE study results showing major motor improvements and reduced mortality risk in SMA patients.
- [Novo Nordisk Cuts Wegovy and Ozempic Self-Pay Price to $199 in New Access Push](https://synopulse.com/novo-nordisk-cuts-wegovy-and-ozempic-self-pay-price-to-199-in-new-access-push/): Novo Nordisk has introduced a $199 introductory price for Wegovy and Ozempic starter doses, alongside a permanent drop in monthly self-pay costs to $349.
- [J&J’s $3B Halda Deal Sets Up $50B Oncology Push](https://synopulse.com/jjs-3b-halda-deal-sets-up-50b-oncology-push/): J&J is acquiring Halda Therapeutics for $3.05B, gaining a precision prostate cancer therapy and a breakthrough induced-proximity platform.
- [Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 10, 2025](https://synopulse.com/synopulse-weekly-pulse-access-decisions-regulatory-events-market-dynamics-week-of-nov-10-2025/): Advertisement The Week’s Biggest Shifts in Payer Strategy This week’s policy and access landscape was defined by a sweeping overhaul of U.S. Medicaid drug pricing and a widening push toward value-driven reimbursement models. CMS’ newly announced GENEROUS model, paired with Most Favored Nation (MFN) pricing agreements for GLP-1s, marks a structural shift that will reshape affordability and state-level negotiations through 2026. Meanwhile, the UK extended its VPAG 2026 exit-decision deadline for the third time, giving manufacturers more room to navigate pricing uncertainty amid shifting global cost-containment pressures. These moves come as FDA expanded the National Priority Voucher program to six additional ... Read more
- [EMA, CHMP NOVEMBER 2025 MEETING: TEN NEW APPROVALS, FOUR INDICATION EXTENSIONS](https://synopulse.com/ema-chmp-november-2025-meeting-ten-new-approvals-four-indication-extensions/): CHMP’s November 2025 meeting delivered 10 new drug approvals, four indication extensions, and several high-profile withdrawals, highlighting continued momentum in gene therapy, oncology, immunology, and diagnostics.
- [UK VPAG DECISION DEADLINE EXTENDED AGAIN](https://synopulse.com/uk-vpag-decision-deadline-extended-again/): The UK and ABPI have agreed to a third extension of the VPAG withdrawal deadline, moving it to December 16, 2025.
- [US CUTS SWISS TARIFFS TO 15% AS SWITZERLAND PLEDGES $200B INVESTMENTS](https://synopulse.com/us-cuts-swiss-tariffs-to-15-as-switzerland-pledges-200b-investments/): Advertisement A stylized U.S. – Swiss handshake over rising economic indicators reflects the sweeping new trade deal tariffs slashed to 15% and Switzerland pledging $200B in U.S. investment through 2028. (Editorial Illustration) The United States and Switzerland have announced a major framework trade agreement that will see Washington slash tariffs on Swiss imports from 39% to 15%, while Swiss companies will commit to $200 billion in U.S. investments by 2028. The move represents one of the largest investment pledges ever made by Swiss industry into the U.S. market and follows intensified negotiations between the two governments. What You Need To Know ... Read more
- [ABL Bio's Grabody lands record heigh $2.6B deal with Lilly](https://synopulse.com/abl-bios-grabody-lands-2-6b-deal-with-lilly/): ABL Bio has signed a major license and research collaboration with Eli Lilly worth up to $2.602 billion, granting access to its Grabody bispecific platform.
- [Cidara Therapeutics Stock sky-Rockets on $9B Merck buyout](https://synopulse.com/cidara-therapeutics-9b-merck-buyout/): Merck’s $9.2 billion acquisition of Cidara brings CD388, a Phase 3 long-acting influenza antiviral, into its pipeline while adding the Cloudbreak® drug-Fc conjugate platform for future oncology and infectious-disease programs.
- [Spain Expands Newborn Screening Portfolio and Launches National Asbestos Injury Certification in Dual Public Health Overhaul](https://synopulse.com/spain-expands-newborn-screening-portfolio-and-launches-national-asbestos-injury-certification-in-dual-public-health-overhaul/): Advertisement Spanish health official displays a Ministry of Health certificate for asbestos-related injury, as Spain rolls out its new national certification system alongside expanded neonatal screening reforms. (Editorial illustration.) CISNS approves sweeping updates to neonatal diagnostics and formalizes a nationwide system to certify asbestos-related disease for compensation Spain’s Interterritorial Council of the National Health System (CISNS) has approved two major public health measures that materially expand early-detection capabilities and strengthen national protections for citizens harmed by asbestos exposure. The dual decisions announced in separate Ministry of Health releases mark one of the most significant simultaneous updates to Spain’s screening and environmental ... Read more
- [FDA Unveils Plausible Mechanism Pathway to Accelerate Bespoke Gene Editing Therapies](https://synopulse.com/fda-unveils-pathway-for-gene-editing-therapies/): FDA officials Vinay Prasad and Marty Makary have unveiled a new “plausible mechanism pathway” designed to accelerate bespoke gene-editing therapies.
- [ICER Releases Draft Scope on COVID-19 Vaccines](https://synopulse.com/icer-releases-draft-scope-on-covid-19-vaccines/): The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document outlining its plans to assess the long-term clinical and economic value of updated COVID-19 vaccines.
- [Lilly Doubles Down on Genetic Medicines with $1.6B RNAi and Gene Therapy Alliances](https://synopulse.com/lilly-alliances-genetic-medicines-with-rnai-gene-therapy/): Eli Lilly has signed back-to-back collaborations with SanegeneBio and MeiraGTx, advancing its genetic medicine portfolio across RNA interference and ophthalmic gene therapy. Together, the agreements deepen Lilly’s position in next-generation RNA- and DNA-based therapeutics.
- [TLV Endorses Keytruda Combo for Advanced Cervical Cancer with Cost-Effectiveness Caveats](https://synopulse.com/tlv-endorses-cost-effectiveness-for-keytruda/): Sweden’s TLV has published its health economic assessment of Merck’s Keytruda for locally advanced cervical cancer, finding clear efficacy benefits when added to chemoradiation. However, the agency warns that cost-effectiveness hinges on price transparency and real-world survival durability.
- [FDA Unveils Second Wave of National Priority Voucher Winners, Featuring Obesity Leaders Lilly and Novo Nordisk](https://synopulse.com/fda-unveils-second-wave-of-national-priority-voucher/): Advertisement Scientists and staff walk outside the U.S. Food and Drug Administration headquarters, representing the agency’s growing focus on regulatory innovation and public health priorities. (AI-generated for editorial illustration purposes.) FDA expands National Priority Voucher pilot with six new awardees, bringing total to 15 therapies The U.S. Food and Drug Administration (FDA) has announced a significant expansion of its Commissioner’s National Priority Voucher (CNPV) pilot program, adding six new recipients to a growing list of therapies chosen for accelerated review under the agency’s new regulatory innovation framework. The six new awardees Zongertinib for HER2 lung cancer, Bedaquiline for pediatric drug-resistant tuberculosis, ... Read more
- [CMS' Medicaid drug payment model brings Trump's MFN push](https://synopulse.com/us-launches-medicaid-drug-payment-model-bring-mfn/): Advertisement CMS’ Medicaid drug payment model links value-based pricing and international benchmarks to lower costs and improve patient outcomes. (Editorial illustration.) US government aims to lower Medicaid drug prices and align costs with global rates under new GENEROUS model The US government has launched a sweeping initiative to reduce prescription drug costs under the Medicaid program, unveiling a new Medicaid drug payment model that ties reimbursement to international benchmarks and measurable clinical value. The Centers for Medicare & Medicaid Services (CMS) announced the plan called the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model as a cornerstone of a broader effort ... Read more
- [Pfizer wins $10 billion bidding war for Metsera after competitive bidding with Novo Nordisk](https://synopulse.com/pfizer-wins-10-billion-bidding-war-for-metsera/): Advertisement Months of legal challenges, court rulings, and regulatory probes define the industry’s fiercest metabolic takeover fight Pfizer has signed a definitive agreement to acquire metabolic biotech Metsera, ending months of one of the most aggressive takeover battles in recent biopharma history. The deal concludes a dramatic contest with Novo Nordisk, which had initially secured Metsera’s board recommendation with a rival $10 billion offer before becoming entangled in litigation and regulatory review. The Metsera acquisition saga began in early 2025, when both companies targeted the metabolic drug developer for its portfolio of dual- and tri-agonist peptide therapies addressing obesity, diabetes, and ... Read more
- [Dutch Healthcare Institute Limits Early Access to Obesity Drugs Amid Cost and Evidence Concerns](https://synopulse.com/dutch-institute-limits-access-obesity-drugs-amid-cost-and-evidence-concerns/): The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.
- [Thailand launches drug access program to slash household medical bills by 32B baht](https://synopulse.com/thailand-drug-access-program-slash-bills-by-32b-baht/): Thailand is letting patients fill hospital prescriptions at registered pharmacies under a new initiative expected to save households 32 billion baht annually. Officials say the program will ease private-sector pricing pressure and improve drug access nationwide.
- [Takeover Battle: Novo Nordisk Wins Brave Court Victory in $10B Metsera Deal Amid FTC Probe](https://synopulse.com/novo-nordisk-clears-hurdle-in-10b-metsera-takeover/): Novo Nordisk’s $10 billion takeover for Metsera has survived a Delaware court challenge from Pfizer but now faces federal scrutiny from the FTC.
- [Scilex Secures Exclusive Global License for Tokenizing Biotech Assets Through Datavault AI Platform](https://synopulse.com/scilex-secures-global-license-for-datavault-platform/): Advertisement Scilex Holding Company has announced an exclusive global license from Datavault AI to tokenize and monetize genomic, diagnostic, and therapeutic data ushering in a new digital framework for valuing real-world biotech assets. The agreement allows Scilex to use Datavault’s proprietary AI-driven platform to create a Biotech Exchange, a marketplace designed to securely trade and fund biotechnology innovations. Scilex believes the potential tokenized market could exceed $2 trillion, spanning pharmaceutical and diagnostic sales. The license covers a robust IP suite including pending patents like “Platform and Method for Tokenizing DNA Data” and issued U.S. patents for secure data handling laying the ... Read more
- [Metsera Board Declares Novo Nordisk Amended Proposal “Superior” in $10 B Takeover Battle](https://synopulse.com/metsera-board-declares-novo-nordisk-takeover-battle/): Metsera’s board has deemed Novo Nordisk’s $10 billion bid superior to Pfizer’s, setting off a high-stakes bidding and legal battle amid the obesity-drug gold rush.
- [Obesity Drug Talks Reach Defining Moment as Lilly and Novo Near Trump Administration Pricing Deal](https://synopulse.com/obesity-drug-talks-lilly-and-novo-trump-deal/): In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.
- [340B Rebate Model Pilot Clears HRSA Approval, Hospitals Warn of New Burdens](https://synopulse.com/340b-rebate-model-pilot-clears-hrsa-approval/): HRSA’s approval of eight manufacturers for its 340B Rebate Model Pilot signals a major pricing shift.
- [Healthcare Reimbursement Overhaul: CMS Promises Major Savings and Triggers Industry Recalibration](https://synopulse.com/healthcare-reimbursement-cms-promises-major-savings/): CMS’s payment modernization plan seeks to trim inefficiencies, curb wasteful spending in wound care, and realign value in Medicare reimbursement. Providers brace for tighter margins as policymakers hail a new era of cost discipline.
- [Bone Cement Treatment Boosts Quality of Life for Patients With Metastatic Cancer](https://synopulse.com/bone-cement-treatment-boosts-metastatic-cancer/): From October 27, 2025, patients in the Netherlands with spinal metastases or multiple myeloma can access bone cement injections. 
- [Lepu Medical Licenses Promising Triple-Agonist Platform to Denmark’s Sidera Bio in Global Metabolic Push](https://synopulse.com/lepu-licenses-triple-agonist-platform-to-sidera-bio/): Lepu Medical expands its biotech footprint through a licensing deal with Sidera Bio for MWN105, a triple-agonist drug targeting obesity and metabolic disorders, combining equity, milestone, and royalty gains in a global partnership.
- [Groundbreaking Collaboration Between Manifold Bio and Roche Launches $2B-Plus Brain-Shuttle Program](https://synopulse.com/manifold-bio-and-roche-launch-2b-plus-collaboration/): Manifold Bio inks a groundbreaking collaboration with Roche to apply AI-guided brain-shuttle technology for neurological therapies.
- [United States and Malaysia Reciprocal Trade Deal Significantly Expands FDA Recognition and Broad Export Access](https://synopulse.com/united-states-and-malaysia-reciprocal-trade-deal/): Malaysia’s acceptance of U.S. FDA certificates under the new U.S.–Malaysia reciprocal trade deal. 
- [NextGen Gene Editing Breakthroughs Redefine Personalized Care](https://synopulse.com/exquisite-breakthroughs-in-personalized-gene-editing/): Advertisement The New Frontier of Gene Editing: From Precision Tools to Personalized Therapies A new generation of programmable gene editing tools is pushing biotechnology toward an era of truly personalized medicine one in which therapies are tailored not only to specific diseases but to individual genetic profiles. As highlighted in a recent npj Biomedical Innovations feature (Nature Portfolio, July 2025), advances in artificial intelligence, data integration, and next-generation CRISPR systems are beginning to merge, transforming how genetic therapies are conceived, tested, and deployed. The convergence points to a future in which biology itself becomes programmable where digital design and molecular engineering ... Read more
- [Metsera responds to Pfizer lawsuit, defends board process in Novo bid dispute](https://synopulse.com/metsera-responds-to-pfizer-lawsuit/): Pfizer’s GLP-1 lawsuit tests biosimilar ambitions and contract guardrails.
- [Cardiac MRI Matches SPECT Accuracy While Eliminating Radiation Risk](https://synopulse.com/stricter-iqwig-stance-on-cardiac-mri-endpoints/): Cardiac MRI is proving its place as a powerful, radiation-free alternative to SPECT in diagnosing coronary artery disease.
- [Brensocatib faces ICER spotlight with strong case for clinical and economic value](https://synopulse.com/icer-final-report-puts-brensocatib-value-to-the-test/): ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
- [Novo’s unsolicited bid for Metsera challenges Pfizer pact](https://synopulse.com/novos-unsolicited-bid-for-metsera-challenges-pfizer/): Novo’s unsolicited Metsera bid could upend Pfizer pact and reshape the GLP-1 race.
- [Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation](https://synopulse.com/cms-and-europe-reimbursement-pathway/): Advertisement In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators and payers accelerating patient benefit, driving innovation uptake, and redefining how clinical value is rewarded. What You Need To Know CMS expands national coverage for renal denervation and cardiac contractility modulation (CCM®) therapy, strengthening U.S. access to device-based cardiovascular care. Sweden’s TLV grants reimbursement for ... Read more
- [New Proposal Calls for Funeral Reimbursement to Boost U.S. Organ Donation](https://synopulse.com/new-proposal-calls-for-funeral-reimbursement/): Funeral reimbursement could transform U.S. organ donation access and equity.
- [Evernorth Secures Breakthrough Pricing Shift in Drug Access](https://synopulse.com/evernorth-secures-pricing-shift-in-drug-access/): Evernorth’s pricing model overhaul transforms drug access and reimbursement dynamics.
- [Baird Medical Secures Pivotal Reimbursement Win for MWA](https://synopulse.com/baird-medical-secures-reimbursement-win-for-mwa/): Successful reimbursement milestone strengthens device adoption and access strategy.
- [Sprouts Launches Bold Lawsuit Challenging Insulin Pricing](https://synopulse.com/sprouts-launches-lawsuit-challenging-insulin-pricing/): Sprouts files lawsuit over insulin pricing scheme and PBM collusion.
- [UK Government Unlocks Game-Changing Drug Pricing Strategy](https://synopulse.com/uk-government-game-changing-drug-pricing-strategy/): UK braces as drug pricing shifts dramatically in market access landscape.
- [Regeneron Unlocks Game-Changing Multispecific Antibody Pact](https://synopulse.com/regeneron-unlocks-multispecific-antibody-pact/): Regeneron boosts its pipeline with multispecific platform for disease innovation.
- [Thermo Fisher's Inspiring $10 Billion Acquisition of Clario](https://synopulse.com/thermofisher-takeover-of-clario-for-10-billion/): Thermo Fisher acquisition hits billion mark for Clario.
- [HAS Stroke Update Transforms Access on World Stroke Day](https://synopulse.com/has-update-transforms-stroke-care-pathway-access/): HAS strengthens stroke management for faster, equitable emergency care access.
- [Reimbursement Series: Anchors Affordable Breakthroughs - AIFA and TLV Expand European Coverage](https://synopulse.com/swedens-reimbursement-shift-spurs-biotech/): Sweden expands reimbursement decisions driving biotech access and patient impact.
- [NICE Secures Breakthrough HTA Decision for Prostate Cancer](https://synopulse.com/nice-secures-hta-decision-for-prostate-cancer/): NICE issues breakthrough HTA decision on Bayer’s prostate cancer therapy.
- [NICE accelerates breakthrough framework for complex liver diseases](https://synopulse.com/nice-accelerates-breakthrough-framework-for-diseases/): NICE drives innovation, reshaping MASH evaluations with transformative guidance.
- [Novartis secures triumphant $12 billion takeover of Avidity](https://synopulse.com/novartis-secures-12-billion-takeover-of-avidity/): The billion-dollar acquisition advances Avidity’s RNA platform with momentum.
- [Biogen Secures Breakthrough Edge in Immunology with $1B Vanqua Buy](https://synopulse.com/biogen-vanqua-immunology-1b-deal/): Biogen strengthens Immunology pipeline through $1B Vanqua acquisition deal.
- [Sanofi Secures Breakthrough FDA Review for Tzield](https://synopulse.com/sanofis-tzield-receives-fda-expedited-review/): Sanofi’s Tzield gains FDA review for stage 3 T1D.
- [Poland Makes Historic Leap in Healthcare: Record Number of New Therapies Now Reimbursed](https://synopulse.com/poland-makes-historic-leap-in-healthcare-record-number-of-new-therapies-now-reimbursed/): Poland's Ministry of Health has announced its largest-ever reimbursement list update
- [Pfizer Throws Down $7.3B Gauntlet in Obesity Race with Metsera Buyout](https://synopulse.com/pfizer-throws-down-7-3b-gauntlet-in-obesity-race-with-metsera-buyout/): After internal setbacks, Pfizer is buying its way into the obesity drug market. 
- [FDA’s BsUFA III Framework: What It Means for Biosimilar Sponsors](https://synopulse.com/fdas-bsufa-iii-framework-what-it-means-for-biosimilar-sponsors/): FDA defines biosimilar PAS & CBE under BsUFA III
- [Focus Brief: Market Access Weekly September 1 to 7, 2025](https://synopulse.com/focus-brief-market-access-weekly-september-1-to-7-2025/): Global market access shifts: HTA speed, UK pricing, digital disruption.
- [The Big Bet: Health Care Deal Spotlight for September 1 to 7, 2025)](https://synopulse.com/the-big-bet-health-care-deal-spotlight-for-september-1-to-7-2025/): Healthcare deal spotlight September 1 to 7, 2025
- [NCPE Recommends Conditional Access for Omeprazole](https://synopulse.com/ncpe-recommends-conditional-access-for-omeprazole/): NCPE recommends Omeprazole Appizped for reimbursement eligibility.
- [NCPE Recommends Vabysmo, Signaling Retinal Policy Shift](https://synopulse.com/ncpe-recommends-vabysmo-signaling-retinal-policy-shift/): NCPE recommends Vabysmo for neovascular (wet) age-related macular degeneration treatment.
- [J&J Launches AI in Surgery Funding via Polyphonic™ Fund](https://synopulse.com/jj-launches-ai-in-surgery-funding-via-polyphonic-fund/): J&J invests $100M in AI in surgery funding to drive smarter surgical solutions.
- [Stryker’s Incompass Total Ankle Wins FDA Clearance](https://synopulse.com/strykers-incompass-total-ankle-wins-fda-clearance/): Stryker FDA-cleared InCompass Ankle; protein degrader partnerships drive innovation.
- [Kymera Strikes License Agreement Deals With Sanofi, Gilead](https://synopulse.com/kymera-strikes-license-agreement-deals-with-sanofi-gilead/): Sanofi, Gilead sign License Agreement with Kymera for protein degrader programs.
- [Hereditary Angioedema Drug From CSL Gains German Backing](https://synopulse.com/hereditary-angioedema-drug-from-csl-gains-german-backing/): Hereditary angioedema therapy by CSL Behring gains positive nod in Germany.
- [FDA Import Ban Disrupts Olympus’ US Medical Supply](https://synopulse.com/fda-import-ban-disrupts-olympus-us-medical-supply/): FDA import ban issued on Olympus medical devices from Japan for quality violations.
- [Judge Rules ReWalk Device Is Medically Necessary for Medicare](https://synopulse.com/judge-rules-rewalk-device-is-medically-necessary-for-medicare/): Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
- [New Reimbursement Strategy Boosts Ambulatory Pay](https://synopulse.com/new-reimbursement-strategy-boosts-ambulatory-pay/): New partnership advances reimbursement strategy for private practices.
- [Vor Bio and RemeGen Seal $4B Global License Agreement](https://synopulse.com/vor-bio-and-remegen-seal-4b-global-license-agreement/): Vor Bio, RemeGen sign Global License Agreement for RC98 development.
- [Novartis Inks $750M Flagship Pact for Cardio Innovation](https://synopulse.com/novartis-inks-750m-flagship-pact-for-cardio-innovation/): Novartis makes a $750M flagship pact to address cardiovascular disease innovation.
- [South Korea’s Drug Pricing Reforms Reshape Market Access Landscape](https://synopulse.com/south-koreas-drug-pricing-reforms-reshape-market-access-landscape/): South Korea’s new pharma pricing reforms reward innovation and expand access for industry.
- [FDA Probes Elevidys Deaths, Stirring Regulatory and Market Uncertainty](https://synopulse.com/fda-probes-elevidys-deaths-stirring-regulatory-and-market-uncertainty/): FDA investigates Elevidys deaths, raising new safety and regulatory questions for gene therapies.
- [Gilead Taps Kymera in $750M Oncology Deal to Harness Molecular Glue Degraders](https://synopulse.com/gilead-taps-kymera-in-750m-oncology-deal-to-harness-molecular-glue-degraders/): Gilead and Kymera seal a $750M deal for innovative CDK2 molecular glue degraders in oncology.
- [Neuron23’s NEU-411 Trial Shifts the Parkinson’s Paradigm Toward Precision](https://synopulse.com/neuron23s-neu-411-trial-shifts-the-parkinsons-paradigm-toward-precision/): Neuron23 advances NEU-411 into Phase II Parkinson’s trial, driven by biomarker-based strategies and strong investor support.
- [NICE Expands TAVI Guidance for Aortic Valve Regurgitation](https://synopulse.com/nice-expands-tavi-guidance-for-aortic-valve-regurgitation/): Advertisement   Quick Summary: NICE has published new interventional procedures guidance recommending the use of transcatheter aortic valve implantation (TAVI) for patients with native aortic valve regurgitation. This guidance enables wider access to TAVI as a less invasive alternative to open-heart surgery for eligible NHS patients, with a key focus on multidisciplinary team-based patient selection and post-procedural outcome monitoring. NICE guidance IPG805 now covers TAVI use for native aortic valve regurgitation (published June 2025). TAVI is recommended as an option for patients unsuitable for surgical aortic valve replacement. Patient selection requires oversight from a multidisciplinary heart team. Annual NHS spend on ... Read more
- [NICE Guidance Catalyzes Digital Mental Health Innovation](https://synopulse.com/nice-guidance-catalyzes-digital-mental-health-innovation/): NICE empowers NHS with digital health tech for children’s mental health, boosting access and efficiency.
- [Benlysta Autoinjector Approval Transforming Pediatric Lupus Nephritis Management](https://synopulse.com/benlysta-autoinjector-approval-transforming-pediatric-lupus-nephritis-management/): GSK’s Benlysta autoinjector gains FDA nod for pediatric lupus nephritis, enabling at-home treatment.
- [SINTX Enters the $1.3B Foot and Ankle Implants Market with SiNAPTIC Acquisition](https://synopulse.com/sintx-enters-the-1-3b-foot-and-ankle-implants-market-with-sinaptic-acquisition/): SINTX acquires SiNAPTIC assets, targeting the $1.3B foot and ankle fusion implant market.
- [Digital Pathology Clearance Accelerates U.S. Market Entry](https://synopulse.com/digital-pathology-clearance-accelerates-u-s-market-entry/): PathPresenter wins FDA clearance for digital pathology viewer, advancing primary diagnosis and LIS integration.
- [TISSIUM’s De Novo FDA Authorization Signals Industry Shift](https://synopulse.com/tissiums-de-novo-fda-authorization-signals-industry-shift/): FDA De Novo nod for TISSIUM’s COAPTIUM CONNECT: a new era in sutureless nerve repair.
- [Revolution Medicines Secures Powerhouse $2B Funding in Groundbreaking Royalty Pharma Deal](https://synopulse.com/revolution-medicines-secures-powerhouse-2b-funding-in-groundbreaking-royalty-pharma-deal/): Revolution inks $2B flexible deal with Royalty Pharma to fund RAS(ON) inhibitors in cancer.
- [Arialys Therapeutics Targets First in Class Precision Therapy for Autoimmune Encephalitis](https://synopulse.com/arialys-therapeutics-targets-first-in-class-precision-therapy-for-autoimmune-encephalitis/): ART5803 targets NMDA receptor autoantibodies, advancing precision therapy for autoimmune encephalitis.
- [Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure](https://synopulse.com/strategic-industry-context-alzheimers-drug-reimbursement-faces-global-pressure/): NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.
- [ENHERTU Advances First-Line Endometrial Therapy in Phase 3 Trial](https://synopulse.com/enhertu-advances-first-line-endometrial-therapy-in-phase-3-trial/): ENHERTU Phase 3 trial launches for first-line endometrial therapy targeting HER2-expressing tumors.
- [Alexion Strikes Bold AI Partnership for Rare Disease Detection](https://synopulse.com/alexion-strikes-bold-ai-partnership-for-rare-disease-detection/): AI partnership targets rare bone disease affecting 1 in 6,000 patients. 
- [ZEISS CLARUS 700 Gains China NMPA Approval for Retinal Imaging](https://synopulse.com/zeiss-clarus-700-gains-china-nmpa-approval-for-retinal-imaging/): ZEISS expands retinal diagnostic capabilities in China with CLARUS 700 ultra-widefield imaging system approval.
- [GoodRx Disrupts Pharmacy Economics with Cost-Plus Pricing](https://synopulse.com/goodrx-disrupts-pharmacy-economics-with-cost-plus-pricing/): GoodRx reshapes independent pharmacy economics through transparent cost-plus pricing model launch.
- [Medacta Showcases Advanced Orthopedic Solutions at ISAKOS](https://synopulse.com/medacta-showcases-advanced-orthopedic-solutions-at-isakos/): Medacta highlights cutting-edge orthopedic innovations at ISAKOS 2024.
- [EMA Links Semaglutide to Rare Vision Loss Risk](https://synopulse.com/ema-links-semaglutide-to-rare-vision-loss-risk/): Two-fold increased risk prompts label updates for blockbuster GLP-1 drugs.
- [Owens & Minor Scraps $1.4B Rotech Deal Amid FTC Opposition](https://synopulse.com/owens-minor-scraps-1-4b-rotech-deal-amid-ftc-opposition/): Medical distributor abandons home healthcare consolidation play.
- [Dupixent Shows Efficacy in Diverse Patient Population](https://synopulse.com/dupixent-shows-efficacy-in-diverse-patient-population/): Dupixent shows 76% efficacy in patients with darker skin tones. 
- [Medtronic Issues Class I Recall for Tracheostomy Tubes](https://synopulse.com/medtronic-issues-class-i-recall-for-tracheostomy-tubes/): Medtronic recalls Shiley trach tubes over flange detachment causing airway complications.
- [J&J Faces $442M Treble Damages Over Catheter Monopoly](https://synopulse.com/jj-faces-442m-treble-damages-over-catheter-monopoly/): J&J's $147M antitrust penalty tripled to $442M for monopolizing cardiac catheter market.
- [UnitedHealth, Humana Back Medicare Home Visit Reforms](https://synopulse.com/unitedhealth-humana-back-medicare-home-visit-reforms/): Major insurers endorse billing limits on controversial home-based risk assessments.
- [RedETSA Convenes 38 HTA Institutions for Americas Summit](https://synopulse.com/redetsa-convenes-38-hta-institutions-for-americas-summit/): Regional HTA network addresses equity, economic evaluation, and adaptation frameworks.
- [Germany Defies Pharma Backlash, Hikes Drug Rebate to 15.5%](https://synopulse.com/germany-defies-pharma-backlash-hikes-drug-rebate-to-15-5/): Advertisement Germany’s lawmakers had no shortage of warnings. Drugmakers objected. Trade groups objected. So did opposition voices inside the country’s own government. The reform passed anyway. Late on Friday, the Bundestag, Germany’s lower house of parliament, approved a health insurance financial reform package by 318 votes to 284, with four abstentions. That is not a comfortable margin. The Bundesrat, the upper house, then gave its blessing, formally clearing the way for the measures to take effect. The change that matters most is a single number that more than doubled. The fixed markdown drugmakers must pay on the list prices of their ... Read more
- [FTC Forces Caremark to Unlock $13B in Patient Savings](https://synopulse.com/ftc-forces-caremark-to-unlock-13b-in-patient-savings/): The FTC has settled its insulin pricing case against Caremark, the CVS-owned pharmacy benefit manager, claiming up to $13 billion in patient savings over the next decade.
- [The Pulse - Biopharma Week in Review: Vertex's $10B Deal, Keytruda Bladder Win](https://synopulse.com/the-pulse-biopharma-week-in-review-vertexs-10b-deal-keytruda-bladder-win/): Advertisement The Pulse – Weekly biopharma intelligence – Synopulse Synopulse The Pulse Synopulse’s weekly biopharma briefing – deals, approvals, readouts and access, across every therapy area. WEEKLY6 – 12 July 2026Wk 28 · 2026 The Hub Neurology19 Onco+Immuno30 CardioMeta17 Approvals The big events this week Deal Vertex acquires Crinetics for $10 billion The week’s largest transaction – an all-cash move that pushes Vertex decisively into rare endocrine disease. Read in CardioMeta → Approval FDA approves Keytruda + Padcev for bladder cancer Merck’s flagship IO-plus-ADC combination extends into earlier-stage, peri-operative bladder cancer. Read in Onco+Immuno → Clinical Oral GLP-1 posts positive Phase ... Read more
- [Two New Non-Invasive Tests Could Slash the Wait for an Endometriosis Diagnosis](https://synopulse.com/two-new-non-invasive-tests-could-slash-the-wait-for-an-endometriosis-diagnosis/): Advertisement Women in the UK wait more than nine years, on average, to be told they have endometriosis. A new pair of tests could start to close that gap and do it without surgery. On 7 July, the National Institute for Health and Care Excellence (NICE) published draft guidance recommending that two non-invasive diagnostic tests, Endotest and EndoSure, be made available on the NHS while the companies behind them gather more evidence. The aim is to give GPs and other primary care staff a faster, gentler way to work out whether a woman’s symptoms point to endometriosis, instead of leaving her ... Read more
- [AlzeCure Pharma Secures a $2.2B QuantumCell Deal for Its NeuroRestore Platform](https://synopulse.com/alzecure-pharma-secures-a-2-2b-quantumcell-deal-for-its-neurorestore-platform/): Advertisement AlzeCure Pharma has found a partner for its Alzheimer’s program, and the numbers attached to the deal are eye-catching, though not all of them in the way the headline suggests. The Swedish biotech said on July 1 that it has signed an out-licensing and collaboration agreement with QuantumCell, a Danish “tech-enabled” biotech, handing over global rights to its NeuroRestore platform and the lead candidate associated with it, ACD856. On paper, the agreement is worth more than $2.2 billion once you tally up the development and commercial milestones, and that figure doesn’t even include royalties. AlzeCure stands to collect tiered royalties ... Read more
- [Boulevard Bio Secures Global Rights to a $1.6B Trispecific T-Cell Engager](https://synopulse.com/boulevard-bio-secures-global-rights-to-a-1-6b-trispecific-t-cell-engager/): Boulevard Bio is paying $20 million upfront and committing up to $1.6 billion in milestones for the global rights to MTS-128, a trispecific T-cell engager.
- [NeuroPulse Wk 26: Cockayne Gene Therapy World-First](https://synopulse.com/neuropulse-wk-26-cockayne-gene-therapy-world-first/): Advertisement NeuroPulse — Wk 26 · 2026 · Synopulse NeuroPulseDeep pine banner. An indigo neural network of neurons and synapses fills the right side, with a gold signal pulse firing along a chain of neurons, beside the NeuroPulse wordmark under the Synopulse and The Pulse kicker. Synopulse · The Pulse NeuroPulse This week in neuroscience Week of 22–28 June 2026 The European Academy of Neurology Congress set the week’s agenda but the standout came from a clinic, not a podium: the first human ever dosed with a gene therapy for Cockayne syndrome. Around it, a run of FDA designations, fresh Phase ... Read more
- [DealFlow: Biopharma Deals This Week June 22–28, 2026](https://synopulse.com/dealflow-biopharma-deals-this-week-june-22-28-2026/): Advertisement DealFlow Weekly — Wk 26 · 2026 · Synopulse DealFlow WeeklyOn a deep pine background, a faint network of the week’s thirty-five deals fades in while a gold deal line draws across and five gold molecular-ring nodes bloom along it, beside the DealFlow Weekly wordmark and the tagline a weekly readout from Synopulse. SYNOPULSE — DEAL INTELLIGENCE DealFlow Weekly A weekly readout from Synopulse 22–28 June 2026 Fifty-eight biopharma deals crossed the wire this week. Five tell you where the industry is pointing two eleven-figure takeouts, an AI land-grab now too big to wave off, and a sharp reminder that ... Read more
- [7 Market Access Trends Reshaping Pharma by 2027](https://synopulse.com/7-market-access-trends-reshaping-pharma-by-2027/): The rules of pharmaceutical market access are being rewritten. From IRA-mandated price ceilings to AI-driven outcomes contracting.
- [Pfizer and Innovent Strike $10.5B Oncology Collaboration](https://synopulse.com/pfizer-and-innovent-strike-10-5b-oncology-collaboration/): Pfizer has signed one of the year's largest cross-Pacific oncology deals, pledging $650 million upfront and up to $9.85 billion in milestones to co-develop 12 early-stage cancer assets with China's Innovent Biologics.
- [The ADC Decade Accelerates: What to Watch at ASCO 2026](https://synopulse.com/the-adc-decade-accelerates-what-to-watch-at-asco-2026/): The antibody–drug conjugate field arrives at ASCO 2026 in a fundamentally different shape. This Synopulse pre-conference briefing maps the five catalysts, 16+ assets, and strategic themes that will reshape the competitive landscape.
- [The Biologics Patent Cliff: Inside Pharma's 2026-2029 Reckoning](https://synopulse.com/the-biologics-patent-cliff-inside-pharmas-2026-2029-reckoning/): A four-year window will reshape biopharma: ten blockbuster biologics worth $136B in annual revenue face biosimilar competition between 2026 and 2029.  
- [Lilly's Quiet $21B Sprint: Seven Deals, One Strategy Hiding in Plain Sight](https://synopulse.com/lillys-quiet-21b-sprint-seven-deals-one-strategy-hiding-in-plain-sight/): While the industry debated whether GLP-1 mania had peaked, Eli Lilly closed seven acquisitions in 134 days. 
- [NHS Gives Green Light to Life-Changing SMA Treatments](https://synopulse.com/nhs-gives-green-light-to-life-changing-sma-treatments/):  NICE has recommended routine NHS access to nusinersen and risdiplam for spinal muscular atrophy.
- [EU Critical Medicines Act Fights Dangerous Supply Crisis](https://synopulse.com/eu-critical-medicines-act-fights-dangerous-supply-crisis/): The EU's Critical Medicines Act takes direct aim at the supply chain vulnerabilities that leave patients without essential drugs when it matters most.
- [February 2026 Deal Report: Five Signals from $53B in Activity](https://synopulse.com/february-2026-deal-report-five-signals-from-53b-in-activity/): February 2026 recorded 218 biopharma transactions totalling $53B in disclosed value.
- [Lilly to buy Ventyx for $1.2B, bolstering oral inflammation pipeline](https://synopulse.com/lilly-to-buy-ventyx-for-1-2b-bolstering-oral-inflammation-pipeline/): Lilly acquires Ventyx to expand oral inflammation pipeline. 
- [NICE backs digital asthma tools for NHS use as evidence builds](https://synopulse.com/nice-backs-digital-asthma-tools-for-nhs-use-as-evidence-builds/): Advertisement The UK health watchdog National Institute for Health and Care Excellence (NICE) has recommended a suite of digital platforms to help people with asthma better manage their condition, signalling growing confidence in app-based tools as part of routine care, while stopping short of full endorsement pending further evidence. In draft guidance published yesterday, NICE said eight digital asthma management platforms can be used across the NHS during a three-year evidence generation period, giving patients and clinicians early access while additional data are collected on clinical outcomes and cost effectiveness. The technologies allow people with asthma to use smartphone apps or ... Read more
- [IQWiG Highlights Evidence Gaps Despite Growing Treatment Options](https://synopulse.com/iqwig-highlights-evidence-gaps-despite-growing-treatment-options/): Advertisement Last week’s policy signals from Germany underscored a clear regulatory theme: access increasingly hinges on comparative evidence, not just innovation or unmet need. New assessments from the Institute for Quality and Efficiency in Health Care (IQWiG) highlighted where evidence is strong enough to support added benefit, where gaps remain despite growing treatment options. Multiple myeloma: More drugs, but not more certainty IQWiG took a cautious stance on linvoseltamab, a bispecific antibody approved in later-line multiple myeloma, concluding that the field currently faces more unmet evidence needs than unmet medical needs. While linvoseltamab received conditional EU approval in 2025 based on ... Read more
- [Lilly taps InduPro’s proximity-guided platform in up to $950M oncology deal](https://synopulse.com/lilly-taps-indupros-proximity-guided-platform-in-up-to-950m-oncology-deal/): Advertisement Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake in InduPro. InduPro will lead early discovery, while Lilly retains downstream development and commercialization rights. At the center of the deal is InduPro’s proximity-guided discovery platform, which identifies Tumor Associated Proximity Antigens (TAPAs), cell-surface proteins that are spatially co-localized with traditional tumor-associated antigens within the ... Read more
- [Neuropulse Daily: January 8, 2026](https://synopulse.com/neuropulse-daily-january-8-2026/): Advertisement Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Valued Over $1B Pulse: Compass Pathways Partners With Radial to Shape Psilocybin Care Delivery Pulse: Bial Launches KYNMOBI in the UK for Parkinson’s OFF Episodes Pulse: NeuraLight Completes Landmark Parkinson’s Biomarker Trial Pulse: EA Pharma Initiates Phase 3 Evenamide Trial in Schizophrenia Pulse: Rapport Therapeutics Accelerates Phase 3 Epilepsy Program Pulse: Herantis Reports Biomarker Evidence Supporting Parkinson’s Therapy Pulse: Sarepta Files CTA for First-in-Human Huntington’s siRNA Therapy Pulse: FDA Accepts Compass IND for Late-Stage PTSD Trial Pulse: Related news Neuropulse Daily: January 8, 2026 Advertisement
- [Lilly in advanced talks to buy Ventyx in a deal topping $1B](https://synopulse.com/lilly-in-advanced-talks-to-buy-ventyx-in-deal-topping-1b/): Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
- [Lilly Reups With Nimbus in $1.3B Oral Obesity Deal](https://synopulse.com/lilly-reups-with-nimbus-in-1-3b-oral-obesity-deal/): Eli Lilly has signed a new collaboration with Nimbus Therapeutics worth up to $1.3B to develop a novel oral obesity drug.
- [NeuroPulse Daily January 7, 2026](https://synopulse.com/neuropulse-daily-january-7-2026/): Advertisement VB Spine Completes Acquisition of Stryker’s Cestas Manufacturing Facility Pulse: Anavex Receives Constructive FDA Feedback on Alzheimer’s Disease Program Pulse: Newleos Therapeutics Doses First Patient in Phase 2 SOAR Study for Social Anxiety Disorder Pulse: Lysoway Therapeutics Advances LW-1017 to Phase I Readiness in Neurodegeneration Pulse: LoQus23 Nominates LQT-23 as First-in-Class Oral Drug Candidate for Huntington’s Disease Pulse: Oculis Receives FDA Breakthrough Therapy Designation for Privosegtor in Optic Neuritis Pulse: FDA Grants Breakthrough Therapy Designation to Alixorexton for Narcolepsy Type 1 Pulse: Newron Expands Evenamide IP With New EU Composition of Matter Patent Pulse: Related news NeuroPulse Daily: January 05, ... Read more
- [Ikarovec Eyes $1B Deal to Move Eye Gene Therapy In-Office](https://synopulse.com/ikarovec-eyes-1b-deal-to-move-eye-gene-therapy-in-office/): UK biotech Ikarovec teams with VectorBuilder on eye gene delivery.
- [NeuroPulse Daily: January 05, 2026](https://synopulse.com/neuropulse-daily-january-05-2026/): Daily neurology update covering Alzheimer’s, Parkinson’s, epilepsy, ADHD. 
- [NICE Clears MS Treatment Option Suitable During Pregnancy](https://synopulse.com/nice-clears-ms-treatment-option-suitable-during-pregnancy/): NICE backs natalizumab for highly active relapsing MS.
- [NICE Backs Age-Based Blood Test to Spot Ovarian Cancer](https://synopulse.com/nice-backs-age-based-blood-test-to-spot-ovarian-cancer/): NICE proposes age-based CA125 testing to improve early diagnosis. 
- [Sanofi, Earendil Lab ink $2.5B deal for bispecific antibody](https://synopulse.com/sanofi-earendil-lab-ink-2-5b-deal-for-bispecific-antibody/): Sanofi has entered a strategic collaboration with Earendil Labs worth up to $2.56B to discover bispecific antibodies.
- [AbbVie Bets $1.2B on Zelgen’s DLL3 Trispecific](https://synopulse.com/abbvie-bets-1-2b-on-zelgens-dll3-trispecific/): AbbVie has licensed ex-China rights to Zelgen’s DLL3 trispecific T-cell engager ZG006 in a deal worth up to $1.2B.
- [Germany Updates Meningococcal, Shingles Vaccine Policy for 2026](https://synopulse.com/germany-updates-meningococcal-shingles-vaccine-policy-for-2026/): Germany adopts new STIKO vaccination recommendations, shifting meningococcal protection to adolescents and expanding shingles eligibility for high-risk adults starting in 2026.
- [EU Finalizes Landmark Pharma Reform to Reset Access and Incentives](https://synopulse.com/eu-finalizes-landmark-pharma-reform-to-reset-access-and-incentives/): The EU reaches a landmark deal on pharmaceutical reform, reshaping regulatory exclusivity, supply obligations, generic entry, and incentives for priority antibiotics.
- [NeuroPulse Today’s Signals: Personalized Neuromodulation, Pediatric Imaging Wins, and Schizophrenia IP Resets](https://synopulse.com/neuropulse-todays-signals-personalized-neuromodulation-pediatric-imaging-wins-and-schizophrenia-ip-resets/): Advertisement NeuroPulse: Today’s Three Signals The neurology sector delivered three distinct signals today, spanning device-led personalization, regulatory expansion in pediatric imaging, and strategic recalibration in neuropsychiatric drug development. Together, they highlight how execution, not novelty, is increasingly determining momentum across neuroscience. Signal One: Soin Neuroscience and BIOTRONIK Push Spinal Cord Stimulation Toward Personalization Soin Neuroscience and BIOTRONIK Neuro announced a research collaboration aimed at advancing personalized spinal cord stimulation (SCS), targeting one of chronic pain therapy’s most persistent challenges: unpredictable patient response. While SCS is well established, outcomes remain highly variable, often limited by static programming models that fail to adapt ... Read more
- [BioMarin to Acquire Amicus for $4.8B in Rare Disease Deal](https://synopulse.com/biomarin-to-acquire-amicus-for-4-8b-in-rare-disease-deal/): BioMarin will acquire Amicus Therapeutics for $4.8B in cash, adding Galafold and Pombiliti + Opfolda and accelerating rare-disease revenue growth.
- [NeuroPulse Daily Brief: December 20, 2025](https://synopulse.com/neuropulse-daily-brief-december-20-2025/): Advertisement In Today’s NeuroPulse, the neurology sector advanced across multiple fronts, with fresh capital flowing into mental health drug development, early clinical milestones reached in brain cancer and neurodegeneration, and regulators extending approvals that lower risk in pediatric imaging and neuromodulation. From nine-figure biotech launches and oversubscribed neurotech seed rounds to first-in-human dosing, personalized spinal cord stimulation research, and data-driven partnerships targeting intracellular CNS biology, the day’s developments reflect a field moving beyond experimentation toward execution. Together, these updates highlight how neuroscience innovation is increasingly anchored in validated mechanisms, clearer regulatory pathways, and platforms designed to translate complexity into clinical impact. ... Read more
- [CMS Confirms 2026 Coverage for MTF’s AmnioBand, AlloPatch](https://synopulse.com/cms-confirms-2026-coverage-for-mtfs-amnioband-allopatch/): CMS confirms Medicare coverage for MTF Biologics’ AmnioBand Membrane and AlloPatch Pliable under updated LCDs for diabetic foot and venous leg ulcers starting 2026.
- [Netherlands Moves to Cut Mental Health Wait Times for 2026](https://synopulse.com/netherlands-moves-to-cut-mental-health-wait-times-for-2026/): The Dutch Healthcare Institute prioritizes group therapy and preventive mental health care to reduce long wait times under its 2026–2028 appropriate care agenda.
- [BioStem Lands 2026 CMS Status Quo Coverage for Skin Grafts](https://synopulse.com/biostem-lands-2026-cms-status-quo-coverage-for-skin-grafts/): CMS places BioStem’s VENDAJE products in a 12-month status quo category, preserving DFU and VLU reimbursement through 2026 while evidence review continues.
- [NeuroPulse Today's Signals: Precision Regulation, RNA Partnerships, and Real-World Data Redefine Neuro Strategy](https://synopulse.com/neuropulse-todays-signals-precision-regulation-rna-partnerships-and-real-world-data-redefine-neuro-strategy/): Advertisement NeuroPulse: Today’s Three Signals The neurology and neurodegeneration landscape is converging around execution rather than exploration. Today’s signals show how late-stage regulatory precision, platform-driven RNA partnerships, and regulator-grade real-world evidence are reshaping the path from discovery to durable market access. Across ALS, Alzheimer’s disease, and RNA-based therapeutics, stakeholders are tightening alignment between data, infrastructure, and commercialization readiness. Signal 1: CAMP4 and GSK Expand RNA Playbook Into Neurodegeneration CAMP4 Therapeutics has entered a strategic research, collaboration, and license agreement with GSK to advance antisense oligonucleotide (ASO) therapies targeting neurodegenerative and renal diseases. The partnership leverages CAMP4’s proprietary RAP Platform®, which maps ... Read more
- [ENvue’s UroShield Secures UK NHS Reimbursement](https://synopulse.com/envues-uroshield-secures-uk-nhs-reimbursement/): ENvue Medical’s UroShield Kit is added to the NHS Drug Tariff Part IX, enabling nationwide reimbursement and triggering early commercial orders in the UK.
- [NeuroPulse Daily Brief: December 19, 2025](https://synopulse.com/neuropulse-daily-brief-december-19-2025/): Advertisement Regulatory momentum, precision diagnostics, and late-stage CNS execution accelerate across neurology Today’s NeuroPulse reflects a neurology sector translating scientific validation into regulatory action, late-stage execution, and scalable infrastructure. Across Alzheimer’s disease, stroke, autism, ALS, epilepsy, and rare neurodevelopmental conditions, the common thread is clear: platforms enabling earlier diagnosis, biologically targeted intervention, and real-world evidence generation are moving from promise to deployment. CAMP4 and GSK Partner on RNA Therapies Pulse:• CAMP4 entered a strategic research and licensing partnership with GSK to develop antisense oligonucleotide therapies for neurodegenerative and renal diseases, highlighting pharma’s expanding interest in RNA amplification beyond traditional gene-silencing approaches.• ... Read more
- [Medline Raises $6.26B in 2025’s Biggest IPO](https://synopulse.com/medline-raises-6-26b-in-2025s-biggest-ipo/): Medline has raised about $6.26B in an upsized IPO, surpassing CATL’s listing to become 2025’s largest debut.
- [NeuroPulse Today's signals: FDA Clears KPAP, RNS Pushes Into Generalized Epilepsy](https://synopulse.com/neuropulse-todays-signals-fda-clears-kpap-rns-pushes-into-generalized-epilepsy/): NeuroPulse tracks today’s three defining neurology events: FDA clearance for adaptive sleep therapy, a pivotal epilepsy PMA filing, and a Phase 3 setback in social anxiety.
- [CMS Reopens National TAVR Coverage Review at Edwards’ Request](https://synopulse.com/cms-reopens-national-tavr-coverage-review-at-edwards-request/): CMS has accepted Edwards Lifesciences’ request to reopen the national coverage determination for TAVR, launching a review that could expand access to asymptomatic patients and ease procedural barriers by late 2026.
- [NeuroPulse Daily Summary: December 18, 2025](https://synopulse.com/neuropulse-daily-summary-december-18-2025/): Advertisement Today’s NeuroPulse tracks critical momentum across neurology, neurotechnology, and CNS drug development, with regulatory clearances, late-stage clinical readouts, and platform expansions reshaping near-term treatment and access dynamics. From FDA progress in epilepsy neuromodulation and adaptive sleep apnea devices to Phase 2 and Phase 3 data in Alzheimer’s disease, social anxiety, and pediatric brain cancer, today’s updates underscore a sector increasingly focused on precision delivery, durable functional outcomes, and scalable deployment across global markets, including India and Europe. Insightec Spins Out Lotus Neuro to Advance Focused Ultrasound Therapies Pulse:• Insightec launched Lotus Neuro as a clinical-stage biotech focused on brain-targeted therapeutics• ... Read more
- [BMS Signs $1.1B Multispecific Antibody Deal With Harbour](https://synopulse.com/bms-signs-1-1b-multispecific-antibody-deal-with-harbour/): Bristol Myers Squibb has entered a global collaboration with Harbour BioMed worth up to $1.1B to discover and develop next-generation multispecific antibodies, strengthening its early-stage immunology and oncology pipeline.
- [Genentech Strikes $1.1B Cancer AI Deal With Caris](https://synopulse.com/genentech-strikes-1-1b-cancer-ai-deal-with-caris/): Genentech has signed a multi-year oncology collaboration with Caris Life Sciences worth up to $1.1B, tapping the techbio’s AI-driven tumor database to discover new solid-tumor targets as year-end dealmaking accelerates.
- [ICER Backs Wegovy, Zepbound Value in Obesity but Flags Access Crunch](https://synopulse.com/icer-backs-wegovy-zepbound-value-in-obesity-but-flags-access-crunch/): Advertisement The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate. In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable and oral) and Eli Lilly’s tirzepatide (Zepbound) all demonstrate a positive net health benefit when added to lifestyle modification, with an independent appraisal committee voting 14–0 in favor of each therapy. Committee members agreed the drugs have fundamentally reshaped obesity care, citing not only substantial ... Read more
- [NeuroPulse Daily: FDA Resets, MS Setback, AR Neurosurgery Gains](https://synopulse.com/neuropulse-daily-fda-resets-ms-setback-ar-neurosurgery-gains/): Advertisement The neurology landscape advanced on multiple fronts today, spanning rare pediatric disease regulation, progressive multiple sclerosis setbacks, epilepsy drug financing, augmented-reality–guided neurosurgery, and expanded commercial reach for psychiatric therapies in Asia. Together, these developments reflect a field balancing regulatory scrutiny with accelerating innovation, particularly in rare disorders, surgical precision, and infrastructure that shortens the path from diagnosis to treatment. Zuellig Pharma Expands Asia Commercial Footprint for Lundbeck’s CNS Portfolio Zuellig Pharma broadened its partnership with Lundbeck to provide full commercialization support for key neuro-psychiatric brands, including Lexapro, Brintellix, and Cipralex across Southeast Asia and Taiwan. The expanded agency model moves ... Read more
- [Zealand, OTR Sign Up to $2.5B Metabolic Drug Deal](https://synopulse.com/zealand-otr-sign-up-to-2-5b-metabolic-drug-deal/): Zealand Pharma’s up-to-$2.5B collaboration with OTR Therapeutics highlights a strategic pivot in metabolic drug development.
- [Yarrow Snags $1.37B TSHR Thyroid Drug From GenSci](https://synopulse.com/yarrow-snags-1-37b-tshr-thyroid-drug-from-gensci/): Advertisement Yarrow lands $1.37B China biotech deal, betting on first-in-class TSHR antibody for thyroid disease U.S.-based Yarrow Bioscience has secured its lead asset through a potential $1.37 billion licensing deal with China’s GenSci Pharmaceutical, picking up ex-China rights to a first-in-class antibody targeting autoimmune thyroid disease as it charts a broader expansion beyond its early platform roots. The agreement announced this Monday grants GenSci subsidiary Shanghai Scizeng Medical Technology $70 million upfront and $50 million in near-term development milestones. Additional development, regulatory, and commercial milestones could increase the total deal value to $1.365 billion, with tiered double-digit royalties on future sales outside of China. ... Read more
- [Sanofi stacks Alzheimer’s bet with second biotech deal of the day, lining up $1B-plus tau antibody pact](https://synopulse.com/sanofi-stacks-alzheimers-bet-with-second-biotech-deal-of-the-day-lining-up-1b-plus-tau-antibody-pact/): Sanofi has signed a global licensing agreement worth up to about $1.04 billion for an early-stage Alzheimer’s antibody targeting acetylated tau, marking the pharma’s second biotech deal of the day as it accelerates external pipeline building in neurology.
- [Dren Bio, Sanofi Expand $1.8B B-Cell Depletion Alliance](https://synopulse.com/dren-bio-sanofi-expand-1-8b-b-cell-depletion-alliance/): Dren Bio has expanded its strategic collaboration with Sanofi in a deal worth up to $1.8 billion, advancing next-generation B-cell depletion therapies and reinforcing deep-remission strategies in autoimmune disease.
- [Sobi Buys Arthrosi to Broaden Gout Franchise and Push Into Chronic Inflammation](https://synopulse.com/sobi-buys-arthrosi-to-broaden-gout-franchise-and-push-into-chronic-inflammation/): Swedish orphan-drug specialist Sobi has agreed to acquire Arthrosi, a privately held biotech focused on next-generation gout therapies
- [EU Greenlights Landmark Pharma Package, Overhauling Drug Rules for the First Time in 20 Years](https://synopulse.com/eu-greenlights-landmark-pharma-package-overhauling-drug-rules-for-the-first-time-in-20-years/): The EU has finalized a sweeping Pharma Package deal, preserving eight years of data protection, adding new antibiotic incentives and giving member states new powers to secure medicine supply.
- [ICER Advances Two High-Stakes Assessments: Cytisinicline Cleared, IgAN Therapies Under Review](https://synopulse.com/icer-advances-two-high-stakes-assessments-cytisinicline-cleared-igan-therapies-under-review/): ICER released two notable updates this week: a final evidence report supporting cytisinicline’s role in smoking cessation and a draft review evaluating sibeprenlimab, atacicept and delayed-release budesonide for IgA nephropathy.
- [NeuroPulse Daily Summary: Regulatory Momentum, Clinical Expansion, and Next-Gen Neurotech Gain Pace](https://synopulse.com/neuropulse-daily-summary-regulatory-momentum-clinical-expansion-and-next-gen-neurotech-gain-pace/): In today’s NeuroPulse Daily, the neurology sector moves forward across regulatory acceleration, digital behavioural health validation, pivotal ALS trial expansion, and spine care reimbursement gains.
- [Teleflex Sells Three Business Units in $2B Portfolio Shift](https://synopulse.com/teleflex-sells-three-business-units-in-2b-portfolio-shift/): Teleflex is unloading its anaesthesia, urology and cardiac care businesses in a trio of deals worth more than $2B.
- [UK Cuts VPAG Newer-Medicine Rate to 14.5% for 2026](https://synopulse.com/uk-cuts-vpag-newer-medicine-rate-to-14-5-for-2026/): The UK has set the 2026 VPAG newer-medicine rebate at 14.5%, down sharply from 22.9% in 2025, reflecting slower NHS uptake and easing budget pressure. With an added 1% contribution, companies will pay 15.5% next year as talks begin to redesign the scheme for 2029 and beyond.
- [NeuroPulse Daily: LumosityRx Secures FDA Nod and Inteligex Drives SCI Regeneration Push](https://synopulse.com/neuropulse-daily-lumosityrx-secures-fda-nod-and-inteligex-drives-sci-regeneration-push/): Today’s neurology landscape delivered major moves across digital therapeutics, gene therapy, neuroimmune modulation, and regenerative medicine, signaling a decisive shift toward clinically validated, translationally focused innovation.
- [Novartis inks $1.7 Billion skin-disease pact with AI startup Relation](https://synopulse.com/novartis-inks-1-7-billion-skin-disease-pact-with-ai-startup-relation/): Novartis and Relation Therapeutics have struck a $1.7 billion collaboration to discover new immuno-dermatology drug targets using Relation’s AI-powered “Lab-in-the-Loop” platform.
- [Pfizer and YaoPharma Forge $2.1B Alliance to Advance Oral GLP-1 Drug](https://synopulse.com/pfizer-and-yaopharma-forge-2-1b-alliance-to-advance-oral-glp-1-drug/): Pfizer has forged an exclusive global partnership with YaoPharma to develop and commercialize YP05002, a small-molecule GLP-1 agonist for chronic weight management.
- [NeuroPulse Daily: DMD Trial, Distal Stroke Data, Lecanemab Access](https://synopulse.com/neuropulse-daily-dmd-trial-distal-stroke-data-lecanemab-access/): Satellos advances a Phase 2 pediatric DMD trial; Rapid completes DISTALS stroke study; lecanemab gains commercial-insurance access in China; ALS and AD platforms progress.
- [Freenome to Go Public in $1.1B SPAC Deal Backed by Perceptive and RA Capital](https://synopulse.com/freenome-to-go-public-in-1-1b-spac-deal-backed-by-perceptive-and-ra-capital/): Freenome is set to become a public company through a SPAC merger with Perceptive Capital Solutions Corp., a deal valuing the multiomics cancer detection developer at roughly $1.1 billion.
- [China’s 2026 NRDL Drives Major Breakthroughs in Drug Access](https://synopulse.com/chinas-2026-nrdl-drives-major-breakthroughs-in-drug-access/): Advertisement China’s latest National Reimbursement Drug List (NRDL), set to take effect on January 1, 2026, is reshaping competitive dynamics across oncology, rare disease, and chronic metabolic care, as a wave of domestic and multinational companies secured new listings or renewed coverage for some of their highest-priority medicines. The update coincides with the release of the country’s first Commercial Health Insurance Innovative Drug Catalog, a complementary mechanism for high-cost or emerging therapies that fall outside basic medical insurance. Together, the dual lists signal a structural acceleration in China’s multi-tier insurance model and continue a multi-year pivot toward increasing affordability and access ... Read more
- [German Court Halts Merck’s Keytruda SC in Major Patent Clash](https://synopulse.com/german-court-halts-mercks-keytruda-sc-in-major-patent-clash/): Merck’s plan to introduce a subcutaneous formulation of Keytruda in Germany has been halted after a Munich court issued a preliminary injunction siding with Halozyme’s patent infringement claims.
- [NeuroPulse Daily: Breakthroughs Across Parkinson’s, Epilepsy and TRS](https://synopulse.com/neuropulse-daily-breakthroughs-across-parkinsons-epilepsy-and-trs/): A high-momentum day across neuroscience as fresh investment, mechanistic innovation, and late-stage readouts tighten the path from discovery to impact.
- [Weekly Pulse: Policy & Access Rules Rewritten for 2026](https://synopulse.com/weekly-pulse-policy-access-rules-rewritten-for-2026/): Advertisement The past week delivered a coordinated sequence of moves that, taken together, quietly reset expectations for how global systems will price, approve, pay for, and ultimately adopt innovation in 2026. What distinguished this week was not the volume of news but its consistency: across borders and agencies, decision-makers leaned into a shared posture, broadened access where evidence is unequivocal, demanded stronger data where uncertainty persists, and pushed the industry toward outcome-anchored models that reward real-world value rather than theoretical promise. Policy Signals Across Borders The trump administration secured another deal at the geopolitical level, this time with the UK. Washington ... Read more
- [Seven NRDL Wins Position Innovent for Volume-Driven Growth in 2025](https://synopulse.com/seven-nrdl-wins-position-innovent-for-volume-driven-growth-in-2025/): Advertisement Innovent Biologics closed out the year with one of its most consequential access wins to date, securing National Reimbursement Drug List (NRDL) inclusion for seven innovative medicines spanning oncology, immunology, metabolism, and rare disease. The breadth of updates underscores how the company’s maturing R&D engine, lifecycle management strategy, and pricing discipline are converging to generate meaningful national coverage at scale. At the center of the announcement is Tyvyt (sintilimab), Innovent’s flagship PD-1 inhibitor co-developed with Eli Lilly. The product secured NRDL reimbursement for its new second-line indication in recurrent or metastatic esophageal squamous cell carcinoma (ESCC). The listing arrives at ... Read more
- [G-BA Clears 2026 Launch of Biologic Substitution Rules](https://synopulse.com/g-ba-clears-2026-launch-of-biologic-substitution-rules/): Germany has cleared the way for pharmacy-level substitution of prescribed biologics with lower-cost biosimilars starting in 2026.
- [White House and London Clinch Drug-Pricing Deal With 25% UK Price Lift](https://synopulse.com/white-house-and-london-clinch-drug-pricing-deal-with-25-uk-price-lift/): The U.S. and U.K. have reached an agreement in principle that lifts U.K. net prices for new innovative medicines by 25 percent, caps VPAG repayments at 15 percent from 2026 onward, and exempts U.K.-origin pharmaceutical and medical goods from Section 232 tariffs.
- [NeuroPulse Daily: Advancing the Alzheimer’s Battle With Early Detection and Novel Mechanisms](https://synopulse.com/neuropulse-daily-advancing-the-alzheimers-battle-with-early-detection-and-novel-mechanisms/): Advertisement The neurology sector moved on several fronts today, with developments spanning Alzheimer’s diagnostics, mitochondrial-targeted drug programs, neuromodulation evidence standards, glioblastoma immunotherapy, spine portfolio restructuring, and new work on surrogate markers in neurodegeneration. Taken together, the updates reflect a field shifting toward earlier disease interception, biomarker-driven precision, and evidence packages that anticipate payer scrutiny. Alzheimer’s continues to command most of the commercial and scientific attention, but activity in epilepsy, GBM, and spine care shows how regulatory expectations and portfolio decisions are increasingly shaping development and launch strategies. Obesity Biomarkers Quantify Faster Alzheimer’s Progression New proteomic data show that obesity accelerates Alzheimer’s ... Read more
- [CMS Sets $1,352 Payment Rate for Pillar’s oncoReveal CDx](https://synopulse.com/cms-sets-1352-payment-rate-for-pillars-oncoreveal-cdx/): Advertisement CMS has issued its final payment determination for Pillar Biosciences’ oncoReveal CDx, confirming a crosswalk-based national rate of $1,352.09, service beginning January 1, 2026. The decision, which aligns with CMS’ preliminary ruling from August, marks a meaningful advance for Medicare beneficiaries and reinforces oncoReveal CDx’s position as a front-line, multi-cancer NGS testing kit in the U.S. market. For Pillar, the finalized pricing represents both reimbursement clarity and a significant commercial inflection point. OncoReveal CDx remains the first PMA-approved multi-cancer IVD kit available in the U.S., offering actionable, NGS-based results that support therapy selection across multiple tumor types. CMS’ determination provides ... Read more
- [NeuroPulse Daily: Key Moves in Fragile X, Meniere’s, DMD, Alzheimer’s Detection, and gMG Access](https://synopulse.com/neuropulse-daily-key-moves-in-fragile-x-menieres-dmd-alzheimers-detection-and-gmg-access/): Today’s neurology cycle delivered four high-impact developments: Mirum’s Phase 2 start in Fragile X, FDA Breakthrough Therapy Designation for SPI-1005 in Meniere’s disease, the U.S. launch of KYMBEE for Duchenne muscular dystrophy, and Circular Genomics’ $15M Series A to advance circRNA-based Alzheimer’s detection.
- [Novo Nordisk Secures Breakthrough MASP-3 Asset in $2.1B Omeros Deal](https://synopulse.com/novo-nordisk-secures-breakthrough-masp-3-asset-in-2-1b-omeros-deal/): Advertisement Omeros has finalized the handoff of its clinical-stage MASP-3 monoclonal antibody zaltenibart (OMS906) to Novo Nordisk, closing a transaction that delivers immediate liquidity, removes near-term financing overhangs, and validates a complement-pathway mechanism increasingly viewed as one of the next competitive frontiers in immunology. The deal, first signed in mid-October, brings Omeros $240 million at closing with total potential economics climbing to $2.1 billion through development, regulatory, and commercial milestones, supplemented by tiered royalties on future sales. The closing marks the formal transfer of all global rights to zaltenibart, a humanized antibody designed to block MASP-3, the upstream activator of complement ... Read more
- [Korea Unlocks Breakthrough Access for Ultomiris and Jemperli](https://synopulse.com/korea-unlocks-breakthrough-access-for-ultomiris-and-jemperli/): Korea delivered two breakthrough reimbursement decisions, opening transformative access to Ultomiris for refractory generalized myasthenia gravis and elevating Jemperli to first-line status in dMMR/MSI-H endometrial cancer.
- [Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24, 2025](https://synopulse.com/weekly-pulse-access-decisions-regulatory-events-market-dynamics-week-of-nov-24-2025/): Advertisement The Reimbursement Landscape Recalibrates As we pause for the Thanksgiving holiday, a sincere thank-you to our readers and partners for your continued engagement. This week’s update reflects a period of meaningful policymaking momentum across major global agencies. Across the U.S., UK, France, Canada and Thailand, agencies delivered firm, directional decisions that shape how hospitals, clinics and payers will fund next-generation therapies in 2026–27. While the outcomes varied, a consistent storyline emerged: systems are rewarding technologies that demonstrate durable clinical value and operational impact, and tightening expectations everywhere else. The U.S. Centers for Medicare & Medicaid CMS dominated the week with ... Read more
- [Reimbursement Wins Reshape Access for SKYRIZI, Tagrisso, Cosentyx](https://synopulse.com/global-reimbursement-momentum-shifts-market-dynamics-across-immunology-and-oncology/): Advertisement Reimbursement Momentum Favours SKYRIZI, Tagrisso and Cosentyx Friday brought major reimbursement shifts in Canada and Korea, recalibrating near-term access in inflammatory bowel disease, EGFR-mutated lung cancer and hidradenitis suppurativa. AbbVie secured a major win in Canada as SKYRIZI moved closer to funded access for ulcerative colitis. In Korea, reimbursement recalibration strengthened Tagrisso’s advantage over Leclaza in EGFR-mutated NSCLC. And Novartis scored a significant dermatology expansion with Cosentyx gaining coverage for severe hidradenitis suppurativa. Together, these decisions highlight how single-day payer actions can shift competitive trajectories across high-burden therapeutic areas. What You Need To Know Canada issues a positive reimbursement recommendation ... Read more
- [Pacira Sues to Block EXPAREL Generics After ANDA Filings](https://synopulse.com/pacira-sues-to-block-exparel-generics-after-anda-filings/): Pacira has sued WhiteOak and Qilu after ANDA filings for generic EXPAREL, initiating a 30-month FDA stay and strengthening its defense of 21 Orange Book patents.
- [AI Wearable EPISERAS Predicts Seizures in Real Time](https://synopulse.com/ai-wearable-episeras-predicts-seizures-in-real-time/): Neuraxpharm and mjn-neuro will launch EPISERAS, an AI-based earpiece that predicts seizures minutes in advance, offering real-time alerts for patients with drug-resistant epilepsy.
- [Repatha Shows Sustained CV Benefit in Largest RWE Study](https://synopulse.com/repatha-shows-sustained-cv-benefit-in-largest-rwe-study/): Advertisement RWE Demonstrates Significant Four-Year MACE Reduction Repatha (Evolocumab), Amgen’s PCSK9 inhibitor, has once again demonstrated its cardiovascular impact, this time in a real-world population exceeding 110,000 patients. New findings presented at the American Heart Association Scientific Sessions 2025 show that the therapy delivers sustained, long-term reductions in major adverse cardiovascular events (MACE) for patients with established atherosclerotic cardiovascular disease (ASCVD), extending the clinical narrative well beyond controlled trial settings. The REPATHA-CE study, conducted by Target RWE in partnership with Amgen, is the largest real-world comparative effectiveness evaluation of evolocumab to date. Drawing on Komodo Health’s Healthcare Map®, which captures de-identified ... Read more
- [NeuroPulse Daily: Next-Gen AI Imaging Debuts, ALS Trial Readiness Builds, and CMS Boosts Neurostimulation Payments](https://synopulse.com/neuropulse-daily-next-gen-ai-imaging-debuts-als-trial-readiness-builds-and-cms-boosts-neurostimulation-payments/): Advertisement AI Imaging Advances, ALS Pipeline Progress, and New CMS Reimbursement Gains Signal Steady Momentum in a Holiday-Quiet Neurology Cycle Even as Thanksgiving week typically slows the flow of biotech and medtech announcements, the neurology sector delivered a trio of meaningful developments across imaging innovation, neurodegenerative drug progress, and federal reimbursement policy. Together, they reflect a field continuing to push toward more precise diagnostics, more resilient clinical programs, and stronger payer alignment heading into 2026. Artificial intelligence in neuroimaging once again took center stage, driven by AIRS Medical’s unveiling of SwiftSight, a new brain-health quantification and reporting platform launching at RSNA ... Read more
- [CMS, Medicaid Expand 2026 Coverage for Five Emerging Health Technologies](https://synopulse.com/cms-medicaid-expand-2026-coverage-for-five-emerging-health-technologies/): Advertisement Broader 2026 Coverage Enhances Economics Across Multiple Care Settings A sweeping set of CMS and Medicaid reimbursement decisions is reshaping 2026 access across neuromodulation, electrophysiology, advanced wound reconstruction, diagnostic testing, and regenerative biologics. From APC assignments and ASC approvals to national pricing and expanded Medicaid coverage, these updates strengthen commercial readiness for emerging technologies while widening patient pathways across Medicare and insured state populations. What You Need To Know CMS announces multiple 2026 reimbursement upgrades across neuromodulation, EP ablation, wound reconstruction, sleep apnea therapy, and DKD diagnostics. Vivistim and Genio both receive APC 1580, securing ~$45K outpatient rates and stronger ... Read more
- [CMS Unveils 2027 Negotiated Prices, Delivering Major Savings Across 15 Drugs](https://synopulse.com/cms-unveils-2027-negotiated-prices-delivering-major-savings-across-15-drugs/): CMS has issued the CY 2026 ESRD PPS final rule, introducing a higher base rate, new geographic adjustments, revised outlier policies, and changes to the ESRD Quality Incentive Program.
- [NeuroPulse Daily: Reimbursement Shifts, ALS/SMA Trial Momentum, and Next-Gen Imaging & Robotic Spine Innovations](https://synopulse.com/neuropulse-daily-reimbursement-shifts-als-sma-trial-momentum-and-next-gen-imaging-robotic-spine-innovations/): This edition of Synopulse’s NeuroPulse tracks major CMS reimbursement boosts, pivotal ALS and SMA milestones, robotic and AI-powered medtech breakthroughs, and new biomarker and neurodevelopment updates shaping tomorrow’s neurology landscape.
- [Merck Canada and pCPA Complete WINREVAIR Negotiations, Advancing Public Reimbursement Pathway for PAH](https://synopulse.com/merck-canada-and-pcpa-complete-winrevair-negotiations-advancing-public-reimbursement-pathway-for-pah/): Advertisement Sotatercept Nears Public Coverage After National Pricing Deal Merck Canada has completed national pricing negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR (sotatercept), marking a significant milestone in the therapy’s journey toward broad public reimbursement across Canada. The agreement, announced on November 20, 2025, positions the first-in-class activin signaling inhibitor one step closer to routine funding through provincial, territorial and federal drug plans . The pCPA, which negotiates on behalf of all publicly funded drug programs, plays a pivotal role in setting the economic framework for medicines entering the Canadian market. Completion of these negotiations does not itself guarantee ... Read more
- [HITAP Launches Global Research Unit to Strengthen Evidence-Informed Health Policy Across LMICs](https://synopulse.com/hitap-launches-global-research-unit-to-strengthen-evidence-informed-health-policy-across-lmics/): Thailand’s HITAP has established the Global Research Unit to address policy questions that traditional HTA cannot fully answer.
- [France Strengthens Cancer Access with TEVIMBRA and New 14-Day Trial Fast-Track](https://synopulse.com/france-strengthens-cancer-access-with-tevimbra-and-new-14-day-trial-fast-track/): Advertisement Breaking Down TEVIMBRA Access and the 14-Day Trial Pathway France has taken two decisive steps to reinforce its clinical research ecosystem and expand access to new oncology therapies. The Haute Autorité de Santé (HAS) has issued a favourable reimbursement opinion for TEVIMBRA (tislelizumab) in gastric and oesophageal cancers, while the National Agency for the Safety of Medicines and Health Products (ANSM), in collaboration with national ethics bodies, has introduced a 14-day fast-track authorization pathway for early-phase and priority clinical trials beginning in early 2026. Although distinct in scope, the paired actions highlight France’s strategic intent: accelerate development, improve market access, ... Read more
- [NICE Issues Two Major 2025 Approvals: Vutrisiran for ATTR-CM and Aucatzyl CAR-T for R/R B-ALL](https://synopulse.com/nice-issues-two-major-2025-approvals-vutrisiran-for-attr-cm-and-aucatzyl-car-t-for-r-r-b-all/): NICE has issued two major decisions: recommending vutrisiran for adult ATTR-CM and approving Aucatzyl CAR-T for relapsed or refractory B-ALL in adults.
- [CMS Sets New Medicare 2026 Rates Across Five Innovation Categories](https://synopulse.com/cms-sets-new-medicare-2026-rates-across-five-innovation-categories/): Advertisement What the New Medicare 2026 Rates Mean for Access and Adoption The U.S. Centers for Medicare & Medicaid Services (CMS) has delivered a rare cluster of reimbursement decisions that collectively mark one of the most significant access-defining weeks of 2025. Spanning neuromodulation, molecular diagnostics, AI imaging, autoimmune disease therapy, and oncology support care, the rulings create new payment pathways that will reshape 2026 utilization across hospitals, imaging centers, ambulatory surgery centers, and physician offices. What You Need To Know CMS issued five major reimbursement decisions impacting neuromodulation, RA neuroimmune therapy, MRD assays, AI cardiac diagnostics and oncology support care. LivaNova, ... Read more
- [NeuroPulse Daily: CMS Stability, PrimeC Phase 3 Approval, and Next-Gen CT Imaging Momentum](https://synopulse.com/neuropulse-daily-cms-stability-primec-phase-3-approval-and-next-gen-ct-imaging-momentum/): Today’s Synopulse NeuroPulse Daily Summary highlights major shifts in neurology, from CMS reimbursement stability and pivotal trial clearances to new medtech platforms and key financing rounds, capturing the most critical regulatory, clinical, and innovation-driven movements shaping the field.
- [NICE Recommends Nanox.AI’s Spine-Fracture Detection Tools for Early Value Assessment Across NHS Hospitals](https://synopulse.com/nice-recommends-nanox-ais-spine-fracture-detection-tools-for-early-value-assessment-across-nhs-hospitals/): NICE has recommended Nanox.AI’s HealthOST and HealthVCF for Early Value Assessment, enabling NHS hospitals to deploy the AI tools for three years while gathering evidence on their value in detecting vertebral fragility fractures. The decision marks an important step in advancing AI-driven early detection of osteoporosis.
- [CMS Finalizes SAINT Payment Stability and Major Reimbursement Gains for NeuroPace’s RNS System](https://synopulse.com/cms-finalizes-saint-payment-stability-and-major-reimbursement-gains-for-neuropaces-rns-system/): CMS has finalized two separate 2026 rulings benefiting neuromodulation innovators: stable outpatient reimbursement for Magnus Medical’s SAINT therapy and significant payment increases for NeuroPace’s RNS System across physician and hospital settings. The updates strengthen patient access and support broader adoption of advanced brain-health technologies.
- [Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 17, 2025](https://synopulse.com/synopulse-weekly-pulse-access-decisions-regulatory-events-market-dynamics-week-of-nov-17-2025/): This week showcased a widening split in global healthcare strategy: payers strengthened cost discipline and evidence demands, while industry advanced AI platforms, precision oncology, and cloud-native diagnostics.
- [GE HealthCare to Acquire Intelerad for $2.3B to Build a Cloud-First Enterprise Imaging Platform](https://synopulse.com/ge-healthcare-to-acquire-intelerad-for-2-3b-to-build-a-cloud-first-enterprise-imaging-platform/): Advertisement GE HealthCare to Acquire Intelerad for $2.3B, Advancing a Cloud-First Imaging Strategy and Expanding Its Reach Across Ambulatory and Hospital Markets GE HealthCare has signed an agreement to acquire Intelerad for $2.3 billion in cash, a move that significantly accelerates the company’s cloud-first transformation and strengthens its position across enterprise imaging in both hospital and rapidly growing outpatient care settings. The deal, announced November 20, is one of GE HealthCare’s most consequential digital-health acquisitions to date and reflects escalating industry demand for unified, AI-enabled imaging platforms that can operate reliably across the full continuum of care. Intelerad, a longtime imaging ... Read more
- [ConcertAI’s TeraRecon Launches DETECT to Align AI Imaging With Reimbursement and Clinical Workflow](https://synopulse.com/concertais-terarecon-launches-detect-to-align-ai-imaging-with-reimbursement-and-clinical-workflow/): ConcertAI’s TeraRecon division has launched DETECT, an AI-first platform designed to close the gap between imaging innovation and reimbursement.
- [Germany Updates Emergency-Care Tiers as IQWiG Questions Daratumumab Benefit in Smoldering Myeloma](https://synopulse.com/germany-updates-emergency-care-tiers-as-iqwig-questions-daratumumab-benefit-in-smoldering-myeloma/): Germany issued two significant regulatory updates: the G-BA expanded its emergency-care tier system by adding a new “non-participation” level, and IQWiG reported that daratumumab shows no proven survival benefit in smoldering multiple myeloma due to flaws in the comparator arm of the AQUILA study.
- [CMS Sets National Pricing for Vesiflo’s inFlow Device, Expanding Access for Women With Permanent Urinary Retention](https://synopulse.com/cms-sets-national-pricing-for-vesiflos-inflow-device-expanding-access-for-women-with-permanent-urinary-retention/): CMS has set national pricing for the inFlow Voiding Prosthesis in the 2026 Medicare fee schedule, expanding access to the only alternative to lifelong catheter use for women with permanent urinary retention.
- [NICE Issues New Updates on AI Cancer Detection, Sepsis Care, and Breast Cancer Drug Appraisal](https://synopulse.com/nice-issues-new-updates-on-ai-cancer-detection-sepsis-care-and-breast-cancer-drug-appraisal/): NICE has published three updates spanning diagnostics, acute care, and oncology: conditional support for AI tools that detect bowel cancer polyps, new sepsis guidelines emphasizing tailored treatment, and the termination of a trastuzumab deruxtecan appraisal after no company evidence submission.
- [NeuroPulse Daily – ASPN PNS Guideline Headlines a Busy Day of Deals, Diagnostics, and Neurotechnology Progress](https://synopulse.com/neuropulse-daily-aspn-pns-guideline-headlines-a-busy-day-of-deals-diagnostics-and-neurotechnology-progress/): Synopulse’s NeuroPulse Daily tracks major movements across neurology, including new Parkinson’s diagnostics, ALS care funding, Huntington’s genetic medicine progress, AI-powered imaging clearance, breakthrough neurotechnology, and multimillion-dollar collaborations accelerating CNS drug discovery.
- [Black Diamond Bought a Licence Instead of a Ruling, and Six Patents Stay Untested](https://synopulse.com/black-diamond-bought-a-licence-instead-of-a-ruling-and-six-patents-stay-untested/): These were not patents on a drug. They were patents on the methods used to find one, and Black Diamond has agreed to pay rather than test them.
- [Australia Cannot Settle Its Device Price Fight While the Service Sits Inside the Price](https://synopulse.com/australia-cannot-settle-its-device-price-fight-while-the-service-sits-inside-the-price/): Both sides are fighting over a number nobody can produce. The evaluation went underneath them and named the reason: the service is inside the price.
- [Oman Is Offering Drug Manufacturers the One Thing Government Procurement Normally Destroys](https://synopulse.com/oman-is-offering-drug-manufacturers-the-one-thing-government-procurement-normally-destroys/): Committing 30% of a health ministry's requirement at agreed prices means deciding not to buy the cheapest product. Somebody is paying for that.
- [Freenome's Lung Test Is Indicated for People Who Never Show Up](https://synopulse.com/freenomes-lung-test-is-indicated-for-the-people-who-never-show-up/): Freenome defined its population by the failure of the existing pathway, not by anything measurable in the patient. That is the decision worth reading.
- [No Product Is Approved for Hernia Prevention. BD Is Spending Five Years to Change That.](https://synopulse.com/no-product-is-approved-for-hernia-prevention-bd-is-spending-five-years-to-change-that/): BD is not testing a product against a competitor. It is testing whether an indication can be brought into existence, with no label, code or precedent.
- [Logical Reasoning Survived Severe Aphasia, and Recruited No Language Regions in Healthy Brains](https://synopulse.com/logical-reasoning-survived-severe-aphasia-and-recruited-no-language-regions-in-healthy-brains/): Two patients with severe aphasia solved formal logic problems as well as controls. The language network stayed quiet through both reasoning types.
- [Korea Cleared Two Diagnostics on One Day, and Both Remove a Specialist](https://synopulse.com/korea-cleared-two-diagnostics-on-one-day-and-both-remove-a-specialist/): Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.
- [FastWave's Pivotal Trial Cannot Measure the Thing FastWave Is Selling](https://synopulse.com/fastwaves-pivotal-trial-cannot-measure-the-thing-fastwave-is-selling/): Everything FastWave sells is comparative. The word its chief executive used is clearance, and clearance means substantially equivalent.
- [The MHRA Authorised Two Obesity Drugs in Two Days. Neither Is on the NHS.](https://synopulse.com/the-mhra-authorised-two-obesity-drugs-in-two-days-neither-is-on-the-nhs/): Two MHRA authorisations in two days. One drug is too common to fund, the other too rare to prioritise. Neither is on the NHS.
- [CMS Opened a Same-Day Coverage Lane for Devices and Closed the Payment Route Underneath It](https://synopulse.com/cms-opened-a-same-day-coverage-lane-for-devices-and-closed-the-payment-route-underneath-it/): CMS Opened a Same-Day Coverage Lane for Devices and Closed the Payment Route Underneath It 
- [Washington Narrowed the Childhood Schedule, and the Insurer Backstop Quietly Stopped Being One](https://synopulse.com/washington-narrowed-the-childhood-schedule-and-the-insurer-backstop-quietly-stopped-being-one/): Washington Narrowed the Childhood Schedule, and the Insurer Backstop Quietly Stopped Being One
- [OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029](https://synopulse.com/orphanpulse-wk-32-tarsus-paid-450m-upfront-for-a-readout-in-2029/): Tarsus committed $450 million at signing for a Stargardt asset whose pivotal trial reads out in 2029, while a competitor is already filing.
- [NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It Yet](https://synopulse.com/neuropulse-wk-32-takeda-fixed-the-cause-and-cannot-ship-it-yet/): FDA approved the first medicine treating narcolepsy type 1 as a disease rather than a symptom set. Takeda cannot sell it for up to ninety days.
- [The Year's Two Largest Conjugate Deals Were Not ADCs, and Not Cancer Drugs](https://synopulse.com/the-years-two-largest-conjugate-deals-were-not-adcs-and-not-cancer-drugs/): Buyers stopped paying for conjugate drugs and started paying for conjugate chemistry. The year's two biggest cheques bought neither an ADC nor a cancer drug.
- [DuPont Spun Chemours Off in 2015. Eleven Years On, Both Are Named in the Same Order.](https://synopulse.com/dupont-spun-chemours-off-in-2015-eleven-years-on-both-are-named-in-the-same-order/): Advertisement QuickCI read/Legal & Policy/Medtech DuPont Spun Chemours Off in 2015. Eleven Years On, Both Are Named in the Same Order. Athithi Verma· 11 August 2026· 3 min read· Synopulse Chief Judge Renée Marie Bumb of the US District Court for New Jersey approved settlements worth more than $2.5 billion on 7 August 2026, resolving claims first filed in 2019 against DuPont, Chemours, Corteva and 3M. The settlements themselves were announced in mid-2025; what happened on Friday was judicial approval, not a new agreement. DuPont, Chemours and Corteva will pay $875 million over 25 years for natural resource and other damages, ... Read more
- [ITM's Complete Response Letter Names No Clinical Concern. It Names a Third-Party Facility.](https://synopulse.com/itms-complete-response-letter-names-no-clinical-concern-it-names-a-third-party-facility/): COMPETE hit its endpoint and is published in The Lancet. The FDA did not touch any of it. What stopped the approval is a facility ITM does not own.
- [Corline's Whole Pulsed Field Upside Depends on One Customer's Regulatory Calendar](https://synopulse.com/corlines-whole-pulsed-field-upside-depends-on-one-customers-regulatory-calendar/): Advertisement QuickCI read/Cardio-Metabolic/Medtech Corline’s Whole Pulsed Field Upside Depends on One Customer’s Regulatory Calendar Athithi Verma· 11 August 2026· 3 min read· Synopulse Corline Biomedical disclosed, under EU market abuse rules and at 08:32 on 10 August 2026, that Health Canada has granted a Medical Device Licence for Kardium’s Globe Pulsed Field System, opening the Canadian market. Corline supplies the CHS heparin surface coating applied to the Globe catheter and has been Kardium’s technology partner for more than eight years. The licence follows FDA approval in September 2025 and marks a second major market for a CHS-coated product. Corline describes pulsed ... Read more
- [MoonLake Says IZAR-1 Met Every Endpoint and Will Not Show You the Placebo Arm](https://synopulse.com/moonlake-says-izar-1-met-every-endpoint-and-will-not-show-you-the-placebo-arm/): MoonLake disclosed 42.1% ACR50 and withheld the placebo arm. An absolute response rate without a comparator is a number, not a result.
- [Teledyne Put Its Antitrust Argument in the Press Release, Product by Product](https://synopulse.com/teledyne-put-its-antitrust-argument-in-the-press-release-product-by-product/): Mehrabian spent a paragraph itemising exactly how the two businesses do not overlap. Executives do that when a competition authority is reading.
- [Jazz Paid $820 Million Upfront for a Phase 1b/2a Because the FDA Pathway Came With It](https://synopulse.com/jazz-paid-820-million-upfront-for-a-phase-1b-2a-because-the-fda-pathway-came-with-it/): Advertisement QuickDeal read/Rare Diseases/Small Molecule Jazz Paid $820 Million Upfront for a Phase 1b/2a Because the FDA Pathway Came With It Athithi Verma· 11 August 2026· 3 min read· Synopulse Jazz Pharmaceuticals will acquire privately held Actio Biosciences for $820 million upfront plus up to $500 million in approval and sales milestones, a maximum of $1.32 billion. That puts roughly 62% of consideration on the table at signing. Both boards approved unanimously and closing is expected by Q4 2026, funded from cash on hand and existing facilities. The asset is ABS-1230, a first-in-class oral small molecule KCNT1 ion channel inhibitor. KCNT1-related ... Read more
- [DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It](https://synopulse.com/dealpulse-signal-wk-32-private-equity-took-the-week-and-paid-cash-for-all-of-it/): Two listed healthcare companies agreed to go private before lunch on Monday. Eighty seven cents of every announced dollar was paid at signing.
- [RiboX's China Trial Data Bought It an Accelerated Dose Titration and a Subcutaneous Route](https://synopulse.com/riboxs-china-trial-data-bought-it-an-accelerated-dose-titration-and-a-subcutaneous-route/): RiboX filed its Chinese investigator-initiated data with the IND. FDA granted faster escalation and a subcutaneous route on the strength of it.
- [Imvanex Now Covers European Two-Year-Olds. The Children Carrying the Burden Are in Africa.](https://synopulse.com/imvanex-now-covers-european-two-year-olds-the-children-carrying-the-burden-are-in-africa/): A type II variation in Brussels does nothing directly for a child in Kinshasa. What it does is unlock the procurement channels that reach one.
- [Replimune Won Accelerated Approval on 91 Evaluable Patients and a 24% Response Rate](https://synopulse.com/replimune-won-accelerated-approval-on-91-evaluable-patients-and-a-24-response-rate/): CBER took a 24% response in 91 evaluable patients, one day after the same committee voted nine to three against Capricor. Measurement, not size.
- [Scholar Rock Filed With Two Fill-Finish Sites. One Just Failed, and the Date Held.](https://synopulse.com/scholar-rock-filed-with-two-fill-finish-sites-one-just-failed-and-the-date-held/): Catalent Indiana failed its FDA inspection. Scholar Rock had named a second fill-finish site in the same BLA, so the PDUFA date did not move.
- [Tau does its damage inside mitochondria, independent of tangles and microtubules. The field's imaging toolkit was built to see neither.](https://synopulse.com/tau-does-its-damage-inside-mitochondria-independent-of-tangles-and-microtubules-the-fields-imaging-toolkit-was-built-to-see-neither/): Tau does its damage inside mitochondria, independent of tangles and microtubules. The field's imaging toolkit was built to see neither.
- [Sphere-9 Can Ablate VT in Europe While Its US Pivotal Is Still Enrolling](https://synopulse.com/sphere-9-can-ablate-vt-in-europe-while-its-us-pivotal-is-still-enrolling/): Medtronic can sell Sphere-9 into ventricular tachycardia in Europe while the trial meant to prove it works in the US is only now enrolling.
- [The FDA Approved Orzeyful and Handed the Approval Date to the DEA](https://synopulse.com/the-fda-approved-orzeyful-and-handed-the-approval-date-to-the-dea/): FDA's letter says the approval date is whenever the DEA publishes scheduling. Takeda holds a first-in-class approval it cannot sell yet.
- [NICE Backed Acalabrutinib and Venetoclax Without Obinutuzumab, and the Omission Is the Decision](https://synopulse.com/nice-backed-acalabrutinib-and-venetoclax-without-obinutuzumab-and-the-omission-is-the-decision/): AMPLIFY tested acalabrutinib and venetoclax with and without obinutuzumab. NICE recommended the doublet, which is a decision about infusions.
- [Argenx's $2.2 Billion Bought a Phase 1b With Ten Patients on Placebo](https://synopulse.com/argenxs-2-2-billion-bought-a-phase-1b-with-ten-patients-on-placebo/): FB102's entire human efficacy dataset in vitiligo is 42 patients, ten of them on placebo. argenx paid $2.2 billion in cash, with no milestones.
- [Medicover Calls India a Distraction. KKR Just Paid 5.4x Revenue for It.](https://synopulse.com/medicover-calls-india-a-distraction-kkr-just-paid-5-4x-revenue-for-it/): Medicover is selling India to buy back management focus. KKR is paying 5.4 times revenue for exactly that. Both can be right.
- [DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead](https://synopulse.com/dealpulse-report-july-2026-vertex-pays-102-as-oncology-cedes-the-lead/): Every July metric fell except the median and the cash share. Vertex paid a 102% premium for Crinetics and carried a fifth of the month alone.
- [Lilly's Volume Rose 60%, Its Realized Prices Fell 13%, and the Top of Its EPS Range Came Down](https://synopulse.com/lillys-volume-rose-60-its-realized-prices-fell-13-and-the-top-of-its-eps-range-came-down/): Advertisement QuickAccess read/Cardio-Metabolic/Peptide Lilly’s Volume Rose 60%, Its Realized Prices Fell 13%, and the Top of Its EPS Range Came Down Athithi Verma· 6 August 2026· 3 min read· Synopulse Eli Lilly reported Q2 2026 revenue of $23.0 billion, up 48%, driven by a 60% increase in volume and partially offset by a 13% decrease in realized prices. Mounjaro reached $9.9 billion in the quarter and $18.6 billion across the half, up 106%. Zepbound reached $9.1 billion across the half, up 60%. US revenue rose 33% to $14.4 billion on 37% volume growth, with realized prices down 3%. Lilly adds that, ... Read more
- [Reckitt's Real Innovation at Mucinex Is the NDA, Not the Twelve Hours](https://synopulse.com/reckitts-real-innovation-at-mucinex-is-the-nda-not-the-twelve-hours/): Almost every OTC cold remedy is sold under the monograph system, which confers no protection at all. Reckitt spent a decade filing its way out.
- [The EPO Revoked BMS's 480mg Opdivo Patent Because the Trial Behind It Dosed by Weight](https://synopulse.com/the-epo-revoked-bmss-480mg-opdivo-patent-because-the-trial-behind-it-dosed-by-weight/): BMS claimed a 480mg flat dose. The only clinical example in its filed application dosed by weight. The EPO revoked the patent on added matter.
- [AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.](https://synopulse.com/astrazeneca-announced-nothing-the-market-charged-it-24bn-anyway/): AstraZeneca closed 9% down on an unconfirmed report of Bristol Myers talks. Roughly $24bn gone, on a conversation neither company will admit to.
- [Pathos Put 6% Down on a Phase III ADC, and Alphamab Kept the Market It Can Actually Reach](https://synopulse.com/pathos-put-6-down-on-a-phase-iii-adc-and-alphamab-kept-the-market-it-can-actually-reach/): Fresenius describes an end to end biopharma business. Dr. Reddy's developed, made and filed this rituximab. Fresenius is only the channel.
- [Dr. Reddy's Developed, Made and Filed the Rituximab. Fresenius Only Sells It.](https://synopulse.com/dr-reddys-developed-made-and-filed-the-rituximab-fresenius-only-sells-it/): Fresenius describes an end to end biopharma business. Dr. Reddy's developed, made and filed this rituximab. Fresenius is only the channel.
- [The 340B Rebate Pilot Is Back at Under 5.5% of Sales, Rebuilt to Survive the Court That Killed It](https://synopulse.com/the-340b-rebate-pilot-is-back-at-under-5-5-of-sales-rebuilt-to-survive-the-court-that-killed-it/): HRSA restarted the 340B rebate pilot at under 5.5% of sales, wrapped in 21 pages of answers to the court that vacated the first one.
- [KKR's 51.8% Premium for Integer Is Measured From Before the Company Said It Was for Sale](https://synopulse.com/kkrs-51-8-premium-for-integer-is-measured-from-before-the-company-said-it-was-for-sale/): KKR's 51.8% premium for Integer is struck to the day before Integer said it was for sale. The 28.8% is what a holder actually gained.
- [Indivior's Holders Take 56.5% and $1 Billion, Supernus Takes the Name, the CEO and the Building](https://synopulse.com/indiviors-holders-take-56-5-and-1-billion-supernus-takes-the-name-the-ceo-and-the-building/): Indivior holders take 56.5% and a billion in cash. Supernus takes the name, the CEO and the building. Equals describes the board seats only.
- [Curium's CVR Waterfall Says It Trusts DEFINITY, Is Betting on Neurology, and Doubts Prostate](https://synopulse.com/curiums-cvr-waterfall-says-it-trusts-definity-is-betting-on-neurology-and-doubts-prostate/): Curium locked 89.5% of consideration in cash and hung the rest on prostate. The CVR waterfall is the buyer's own forecast, published.
- [DealPulse Signal Wk 31: One Buyer Paid Everything, Another Paid a Fifth](https://synopulse.com/dealpulse-signal-wk-31-one-buyer-paid-everything-another-paid-a-fifth/): Two immunology deals, five days apart. argenx paid 100% on signing for Phase 1b. J&J paid 22% for preclinical. Both are correctly priced.
- [OrphanPulse Wk 31: The Panel Voted on a Process, Not a Drug](https://synopulse.com/orphanpulse-wk-31-the-panel-voted-on-a-process-not-a-drug/): FDA advisers voted 9 to 3 against Capricor's deramiocel, three weeks before PDUFA. The argument was not about biology. It was about which SAP counted.
- [NeuroPulse Wk 31: An Open-Label 77% Could Not Rescue a Missed Endpoint](https://synopulse.com/neuropulse-wk-31-an-open-label-77-could-not-rescue-a-missed-endpoint/): FDA told NeuroPace its generalized epilepsy expansion is not approvable as filed. An open-label 77% cannot rescue a randomized endpoint that missed.
- [Congress Exempted the Medically Frail. The Coding System Cannot Find Them.](https://synopulse.com/congress-exempted-the-medically-frail-the-coding-system-cannot-find-them/): Fewer than 500 of 10,000 rare diseases have an ICD-10 code. The Medicaid frailty exemption is verified against codes most patients never had.
- [An FDA Panel Voted 9-3 Against Capricor on Cardiomyopathy and Never Voted on the Endpoint That Passed](https://synopulse.com/an-fda-panel-voted-9-3-against-capricor-on-cardiomyopathy-and-never-voted-on-the-endpoint-that-passed/): The ballot was the outcome. A drug's strongest dataset sitting off the voting question is not a footnote, it is the whole result.
- [Revtorpyk Got Its NCCN Category 1 Listing Two Months Before Celcuity Can Sell a Single Vial](https://synopulse.com/revtorpyk-got-its-nccn-category-1-listing-two-months-before-celcuity-can-sell-a-single-vial/): The reimbursement case is being built before the product exists. Two gates remain, and a guideline solves neither.
- [NICE Backed Aficamten the Same Day the MHRA Authorised It, at a Price It Will Not Disclose](https://synopulse.com/nice-backed-aficamten-the-same-day-the-mhra-authorised-it-at-a-price-it-will-not-disclose/): Concurrent MHRA and NICE decisions collapse the usual access gap to zero. Then read the conditions, because that is where the guidance lives.
- [J&J Paid $785 Million for a Look at Something That Has Never Been in a Human](https://synopulse.com/jj-paid-785-million-for-a-look-at-something-that-has-never-been-in-a-human/): J&J committed $785 million including a $465 million equity stake, plus an option to acquire Sail Biomedicines for $2.58 billion, on a preclinical in vivo CAR-T platform.
- [The Biosimilar Was Too Cheap to Sell. So the Price Went Up Fourfold.](https://synopulse.com/the-biosimilar-was-too-cheap-to-sell-so-the-price-went-up-fourfold/): Byooviz relaunched in the US at an average sales price of $1,190, roughly four times its previous level and above the originator it references.
- [Washington Removed the Cushion Under Part D, and Handed the Auditors an Algorithm](https://synopulse.com/washington-removed-the-cushion-under-part-d-and-handed-the-auditors-an-algorithm/): Washington ended the subsidy holding Part D premiums down, charged a record number of Medicaid fraud defendants, and put prosecutors' analytics inside CMS.
- [AbbVie Took Two EU Approvals in One Day, Both for Diseases Payers Have Called Cosmetic](https://synopulse.com/abbvie-took-two-eu-approvals-in-one-day-both-for-diseases-payers-have-called-cosmetic/): The European Commission approved RINVOQ for non-segmental vitiligo and, the same day, for severe alopecia areata, both in adults and adolescents aged 12 and over.
- [The Alzheimer’s Blood Test Just Moved Into the GP’s Office, Which Is the Whole Point](https://synopulse.com/the-alzheimers-blood-test-just-moved-into-the-gps-office-which-is-the-whole-point/): GPs in North West London are running C2N's Alzheimer's blood test before referral, testing whether accurate amyloid detection works in primary care.
- [A Private Device Company Just Put Its Pivotal Trial Head to Head Against the Market Leader](https://synopulse.com/a-private-device-company-just-put-its-pivotal-trial-head-to-head-against-the-market-leader/): VDyne treated the first patient in a pivotal trial randomising its tricuspid valve replacement head to head against Edwards' commercially available EVOQUE.
- [Brazil Approved Five Semaglutides in a Day. Sandoz Announced One of Them.](https://synopulse.com/brazil-approved-five-semaglutides-in-a-day-sandoz-announced-one-of-them/): ANVISA approved five semaglutide products in a single day, including the one Sandoz will sell. Ozempic's Brazilian patent expired in March.
- [NICE Said Yes to the Lung Machine, and Then Attached Four Years of Conditions](https://synopulse.com/nice-said-yes-to-the-lung-machine-and-then-attached-four-years-of-conditions/): NICE conditionally recommended the XVIVO perfusion system for NHS use, with four years of evidence generation and a hub model to end the postcode divide.
- [Abbott Is Not Testing Whether TriClip Works. It Is Building the File That Gets It Paid.](https://synopulse.com/abbott-is-not-testing-whether-triclip-works-it-is-building-the-file-that-gets-it-paid/): Abbott began a 1,000-patient, five-year post-market study of TriClip across 100 sites, generating the durability evidence payers and guidelines require.
- [A B7-H3 Antibody Drug Conjugate Just Won a Second Phase 3, in a Second Tumour](https://synopulse.com/a-b7-h3-antibody-drug-conjugate-just-won-a-second-phase-3-in-a-second-tumour/): A second positive Phase 3 in a second tumour makes Ris-Rez the only B7-H3 antibody-drug conjugate with late-stage wins across more than one cancer.
- [J&J Won the Ruling on 22 July. Five Days Later It Agreed to Pay $5.5 Billion.](https://synopulse.com/jj-won-the-ruling-on-22-july-five-days-later-it-agreed-to-pay-5-5-billion/): J&J agreed to pay $5.5 billion to resolve roughly 76,000 ovarian talc claims, five days after a court ruling that put plaintiffs in an untenable position.
- [Approval Is Day One. In Canada, Patients Wait Another Five Hundred Days.](https://synopulse.com/approval-is-day-one-in-canada-patients-wait-another-five-hundred-days/): A Canadian government task force counted the wait for public drug coverage: 200 days for HTA, 195 for price negotiation, then up to 219 more per province.
- [Italy Ran an Innovation Test for Eight Years.](https://synopulse.com/italy-ran-an-innovation-test-for-eight-years/): Italy graded new medicines full, conditional or not innovative for eight years. The 2025 reform abolished the middle grade, because almost nothing ever graduated.
- [A New Antibiotic Reached a Middle-Income Country Six Months After the US](https://synopulse.com/a-new-antibiotic-reached-a-middle-income-country-six-months-after-the-us/): Thailand approved a first-in-class oral antibiotic for gonorrhoea six months after the US, a benchmark for how fast new medicines can reach lower-income markets.
- [Argentina Just Made One Agency the Buyer for Five National Hospitals](https://synopulse.com/argentina-just-made-one-agency-the-buyer-for-five-national-hospitals/): Argentina published the decree completing its National Agency of Health Establishments, centralising the administration and procurement of five national hospitals.
- [Britain Thought It Had an Opt-Out. Washington Reads the Deal Differently.](https://synopulse.com/britain-thought-it-had-an-opt-out-washington-reads-the-deal-differently/): Britain believed it had secured an exemption from the MFN reference basket. Washington reads the arrangement differently, and implementation is still being negotiated.
- [Wet AMD’s Problem Was Never the Drug. It Was the Injections.](https://synopulse.com/wet-amds-problem-was-never-the-drug-it-was-the-injections/): Susvimo won a CHMP recommendation as Europe's first continuous-delivery wet AMD treatment, replacing monthly eye injections with two implant refills a year.
- [ADCs Graduated From Salvage to First Line, Twice in a Week](https://synopulse.com/adcs-graduated-from-salvage-to-first-line-twice-in-a-week/): Enhertu with pertuzumab and Trodelvy with Keytruda both won CHMP opinions for first-line metastatic breast cancer, moving ADCs from last resort to standard.
- [Europe Backs the Cholesterol Class That Failed Four Times](https://synopulse.com/europe-backs-the-cholesterol-class-that-failed-four-times/): Europe recommended approval for a CETP inhibitor, a class with four prior failures, on LDL-lowering trials. The outcomes trial that decides it has not read out.
- [The Cheapest Drug in Retina Just Became a Branded Product](https://synopulse.com/the-cheapest-drug-in-retina-just-became-a-branded-product/): LYTENAVA becomes the first FDA-approved ophthalmic bevacizumab for wet AMD, with 12 years of exclusivity, on a molecule already used in most first-line treatment.
- [China Stopped Excluding Patented Drugs From Its Price Cuts. Now the Bidder Signs for the Risk.](https://synopulse.com/china-stopped-excluding-patented-drugs-from-its-price-cuts-now-the-bidder-signs-for-the-risk/): Eight patent-sensitive molecules were admitted to China's price-cutting round on one condition: the bidder signs an intellectual property undertaking and carries the risk.
- [OrphanPulse Wk 30: CHMP Backs a Drug It Refused Twice](https://synopulse.com/orphanpulse-wk-30-chmp-backs-a-drug-it-refused-twice/): Nezglyal was refused in February 2024 and again in May. This week the same committee recommended it, and children with cerebral ALD get an oral option.
- [NeuroPulse Wk 30: Three Orexin Programmes in Two Weeks](https://synopulse.com/neuropulse-wk-30-three-orexin-programmes-in-two-weeks/): Lundbeck's Fast Track makes three orexin programmes in two weeks. Plus a Duchenne filing with a January date, and a CHMP slip caused by a contract manufacturer.
- [DealPulse Signal Wk 30: Three Billion-Dollar Deals, No Drugs](https://synopulse.com/dealpulse-signal-wk-30-three-billion-dollar-deals-no-drugs/): Dassault took a safety-data platform, Tempus took the diagnostics layer it already sold, Repligen took biopreservation tools. Three deals, no molecules.
- [Agilent Has Built an Annuity on Merck’s Clinical Programme, One Indication at a Time](https://synopulse.com/agilent-has-built-an-annuity-on-mercks-clinical-programme-one-indication-at-a-time/): Agilent won its eighth CE-marked companion diagnostic indication for a single PD-L1 assay, each one riding on a label expansion Merck paid to generate.
- [China Approved the World’s First Once-Daily Oral Factor B Inhibitor, and a US Small-Cap Licensed It a Month Early](https://synopulse.com/china-approved-the-worlds-first-once-daily-oral-factor-b-inhibitor-and-a-us-small-cap-licensed-it-a-month-early/): China approved Haisco's ciprocopan for PNH, the world's first once-daily oral complement Factor B inhibitor, a month after a US small-cap licensed ex-China rights.
- [Accord’s Denosumab Biosimilars Launch With Cigna Preferred Status Already Secured](https://synopulse.com/accords-denosumab-biosimilars-launch-with-cigna-preferred-status-already-secured/): Accord made two interchangeable denosumab biosimilars commercially available with Cigna preferred status already secured on the pharmacy benefit since 1 July.
- [One Robot, Three Ways In: Momentis Clears Multiport a Day After J&J Shrank the Footprint](https://synopulse.com/one-robot-three-ways-in-momentis-clears-multiport-a-day-after-jj-shrank-the-footprint/): Momentis won FDA clearance for multiport surgery, making Anovo the first robotic platform cleared for natural orifice, single-port and multiport approaches.
- [A Company Called StrokeDx Just Cleared a Device That Is Not Cleared to Detect Stroke](https://synopulse.com/a-company-called-strokedx-just-cleared-a-device-that-is-not-cleared-to-detect-stroke/): NeuraNova, formerly StrokeDx, won FDA clearance for a bedside device measuring cerebral fluid asymmetry, cleared as an adjunct rather than a diagnostic.
- [Dassault Paid $1.8B Cash for the Company That Processes 12 Million Safety Reports a Year](https://synopulse.com/dassault-paid-1-8b-cash-for-the-company-that-processes-12-million-safety-reports-a-year/): Dassault Systèmes will pay $1.8 billion cash for ArisGlobal, whose platform processes more than 12 million patient safety reports annually for 200 customers.
- [Trump Wants Generics Made in America by 2028. The Economics Say They Can’t.](https://synopulse.com/trump-wants-generics-made-in-america-by-2028-the-economics-say-they-cant/): Trump gave generic drugmakers until August 2028 before a 100% tariff, rising to 200% in 2029. The problem is the margin those drugs actually carry.
- [One Trial Miss Cut AstraZeneca’s Cushion Above $80bn to $800m](https://synopulse.com/one-trial-miss-cut-astrazenecas-cushion-above-80bn-to-800m/): A drug worth $1.9bn of 2030 revenue cost AstraZeneca £19bn in a day, leaving roughly $800m of headroom above its $80bn goal with the risky readouts still ahead.
- [PRIMA Can Be Sold in 30 Countries Tomorrow. Reimbursement Is the Real Timeline.](https://synopulse.com/prima-can-be-sold-in-30-countries-tomorrow-reimbursement-is-the-real-timeline/): Science Corp's retinal implant won a CE mark for sale across 30 European countries, after trial patients gained a mean 25.5 letters of visual acuity.
- [Novo Is Suing Lilly Over a Head-to-Head Trial Lilly Won, Arguing the Result Went Stale](https://synopulse.com/novo-is-suing-lilly-over-a-head-to-head-trial-lilly-won-arguing-the-result-went-stale/): Novo Nordisk filed a Lanham Act suit over Lilly's Zepbound ads, arguing a genuine head-to-head result became misleading once a higher Wegovy dose launched.
- [J&J Built Its Surgical Robot Into the Table, and Aimed It at the 92% of Surgery That Isn’t Robotic](https://synopulse.com/jj-built-its-surgical-robot-into-the-table-and-aimed-it-at-the-92-of-surgery-that-isnt-robotic/): The FDA granted De Novo authorization to OTTAVA, the first surgical robot with arms built into the operating table, cutting the footprint by up to half.
- [A Twice-Yearly Injection Cut Clotting Factor XI by 92%, With No Major Bleeding](https://synopulse.com/a-twice-yearly-injection-cut-clotting-factor-xi-by-92-with-no-major-bleeding/): A twice-yearly injection cut clotting Factor XI activity by 92% in coronary artery disease patients, with no major bleeding events in the Phase 2a study.
- [GSK Closed the Nuvalent Deal on 15 July. Seven Days Later, the FDA Approved the Drug.](https://synopulse.com/gsk-closed-the-nuvalent-deal-on-15-july-seven-days-later-the-fda-approved-the-drug/): GSK closed its Nuvalent acquisition on 15 July. The FDA approved Jideytro on 22 July, two months ahead of schedule, making it GSK's first lung cancer drug.
- [A Geneva BCI Company Records Its First Human Neural Data, and Europe Gets a Serious Entrant](https://synopulse.com/a-geneva-bci-company-records-its-first-human-neural-data-and-europe-gets-a-serious-entrant/): ABILITY Neurotech recorded human neural data for the first time during tumour surgery in Munich, its first step toward a long-term implantable brain-computer interface.
- [The Only Non-Drug Pediatric ADHD Device Launches Its Second Generation Into a 1,500-Family Waitlist](https://synopulse.com/the-only-non-drug-pediatric-adhd-device-launches-its-second-generation-into-a-1500-family-waitlist/): The only FDA-cleared non-drug treatment for pediatric ADHD launched its second generation into a 1,500-family waitlist, with reimbursement still the open question.
- [JCR Gets Its Brain-Penetrating Hunter Therapy Out of Japan for the First Time, Through the UAE](https://synopulse.com/jcr-gets-its-brain-penetrating-hunter-therapy-out-of-japan-for-the-first-time-through-the-uae/): IZCARGO, a therapy engineered to cross the blood-brain barrier, won its first marketing authorization outside Japan five years after launching there.
- [Crysvita Reaches One-Month-Old Infants in the EU, and Buys Two More Years of Orphan Exclusivity](https://synopulse.com/crysvita-reaches-one-month-old-infants-in-the-eu-and-buys-two-more-years-of-orphan-exclusivity/): The European Commission approved Crysvita for infants as young as one month with XLH, a decision that also buys Kyowa Kirin two more years of orphan exclusivity.
- [Spain rewrites its drug-pricing rulebook, and the price of a generic will now fall as it sells more](https://synopulse.com/spain-rewrites-its-drug-pricing-rulebook-and-the-price-of-a-generic-will-now-fall-as-it-sells-more/): Spain's new draft Medicines Law will cut the price of generics and biosimilars automatically as their market share grows, replacing a system where prices froze after one initial discount.
- [A Father’s Liver, One Incision: the First Single-Port Robotic Liver Transplant Lands in a Six-Year-Old](https://synopulse.com/a-fathers-liver-one-incision-the-first-single-port-robotic-liver-transplant-lands-in-a-six-year-old/): A six-year-old with a rare genetic liver disorder became the first patient to receive a liver transplant through a single robotic incision, donated by his father.
- [Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four](https://synopulse.com/biotronik-is-quietly-assembling-a-spinal-cord-stim-challenge-to-the-big-four/): Advertisement CI Neurology/Medtech/Neuromodulation Biotronik Is Quietly Assembling a Spinal-Cord-Stim Challenge to the Big Four Athithi Verma· 21 July 2026· 1 min read· Synopulse Biotronik Neuro launched Embrace One on 20 July, an AI capability for its Prospera spinal cord stimulation (SCS) system. It analyses more than 200 remote-monitoring data points per patient per day to flag who may need proactive outreach. The model routes insight to a care team; it does not adjust therapy. In an ASPN pilot, the model surfaced 188 behavioural patterns across 175 patients, and patients responded to outreach in 80.9 percent of cases. The launch lands one ... Read more
- [Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold](https://synopulse.com/tempus-buys-personalis-for-1-5b-to-own-the-mrd-layer-it-already-sold/): Advertisement Deal Oncology/ Diagnostics/ MRD Tempus Buys Personalis for $1.5B to Own the MRD Layer It Already Sold Athithi Verma· 21 July 2026· 1 min read· Synopulse Tempus AI will acquire Personalis at $16.25 per share, a $1.5B enterprise value net of the stake Tempus already held. All-stock, with a cash option capped at 50 percent. Closes late 2026 or early 2027. Converts their November 2023 partnership, under which Tempus already invested in and commercialised Personalis’s NeXT Personal MRD test, into full ownership. Personalis posted $22.4M in Q2 revenue on 10,384 clinical tests, up 33 percent QoQ, with Medicare coverage in ... Read more
- [OrphanPulse Wk 29: Ionis Takes SMA-Proven Antisense Into Dravet Syndrome](https://synopulse.com/orphanpulse-wk-29-ionis-takes-sma-proven-antisense-into-dravet-syndrome/): A week defined by first-in-human starts across rare genetic disease, led by antisense entering Dravet syndrome from the field that already rewrote spinal muscular atrophy. Around it, first patients dosed in rare vascular and cardiomyopathy programs with near-empty competitive fields, a first-in-class readout in heparin-induced thrombocytopenia, and orphan designations that quietly reshape the economics behind them.
- [NeuroPulse Wk 29: First Brain Link Shares Movement Between Two People](https://synopulse.com/neuropulse-wk-29-first-brain-link-shares-movement-between-two-people/): The Alzheimer's Association International Conference drove the week's pipeline news, but the signal that mattered most came from a lab: the first brain link that let one paralysed person move and feel through another. Around it, a tau target validated and contested in the same week, an oral entrant scaling in Huntington's, and anti-amyloid therapy fighting its real battle, which is access.
- [DealPulse Signal Wk 29: The Biggest Deal of the Week Was a Bare Line](https://synopulse.com/dealpulse-signal-wk-29-the-biggest-deal-of-the-week-was-a-bare-line/): Thirty four healthcare deals crossed the wire the week of July 13, 2026. Four of the five that matter paid cash for something that already works: an operating rare-disease pharmacy, an FDA-approved drug, a Phase 3 asset with Breakthrough.
- [NICE Backs Finerenone for 280,000 Heart Failure Patients](https://synopulse.com/nice-backs-finerenone-for-280000-heart-failure-patients/): Advertisement Half of England’s heart failure patients have spent decades watching the other half get all the drugs. That’s the context for what NICE did this week. On 16 July, the institute published final draft guidance recommending finerenone for adults with chronic heart failure with preserved or mildly reduced ejection fraction. NICE estimates up to 280,000 people in England could be eligible a large number by any standard, and a striking one for a condition that has had so little to offer. The split matters. Of the roughly 635,000 people in England living with heart failure, about half have the preserved ... Read more
- [NICE Slashes Medicines Evaluation Times by 30%](https://synopulse.com/nice-slashes-medicines-evaluation-times-by-30/): NICE recommended 66 new treatments last year and rejected seven but 25 evaluations were terminated before anyone ruled on them.
- [DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B](https://synopulse.com/dealflow-h1-2026-ma-doubles-as-upfront-spending-hits-174b/): Advertisement DealFlow H1 2026 Review: M&A Rebounds as Upfront Deal Spending Doubles Synopulse · DealFlow · Healthcare & life sciences dealmaking · H1 2026 review M&A came back big, and wrote the cheque in cash M&A value rose 96% to $188 billion in the first half of 2026 and upfront payments jumped 72%, as acquirers paid up for de-risked assets. The deal count fell 11%. Capital concentrated into fewer, larger, cash-heavy transactions. Advertisement The half in five points M&A retook the lead. M&A generated $188.1B across 301 deals, up 96% year-over-year, edging past licensing ($178.5B) by value while paying roughly twelve ... Read more
- [Genentech Bets $1.5B+ on Earendil’s Bispecifics With $55M Upfront](https://synopulse.com/genentech-bets-1-5b-on-earendils-bispecifics-with-55m-upfront/): The one clean upfront among this week's discovery deals, and Earendil keeps more of the early clinical risk than most.
- [Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront](https://synopulse.com/lilly-innocare-strike-3-35b-pact-heavy-on-milestones-light-on-upfront/): QuickDeal read/Deals Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront Athithi Verma· 24 September 2026· 2 min read· Synopulse InnoCare Pharma, listed in Hong Kong and Shanghai, said on 24 September 2026 that it has signed a strategic research collaboration and licence agreement with Eli Lilly. InnoCare will use its discovery platform to find and advance compounds against up to 5 targets. Neither the targets nor the therapeutic areas were disclosed. InnoCare is eligible for up to $100m in upfront and near-term payments, up to about $3.25bn in development and commercial milestones, and single-digit tiered royalties on net ... Read more
- [J&J Is Using Two Tecvayli Trials to Own Myeloma's First Relapse Whether or Not Patients Had Darzalex](https://synopulse.com/jj-is-using-two-tecvayli-trials-to-own-myelomas-first-relapse-whether-or-not-patients-had-darzalex/): J&J's frontline success with Darzalex is manufacturing the monotherapy market for Tecvayli at first myeloma relapse.
- [Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment](https://synopulse.com/henlius-licensed-a-us-ph-switch-platform-for-two-t-cell-engager-targets-without-disclosing-any-payment/): Henlius bought a switch, not a molecule, and the deal discloses no dollar figure at all, not even a headline total.
- [Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria](https://synopulse.com/roche-claims-best-in-class-potential-for-sefaxersen-without-disclosing-how-much-it-cut-proteinuria/): Sefaxersen hits the same target as Novartis's Fabhalta. Roche withheld the one number that would show which drug does more.
- [A Court Vacated the FDA's Biologic Classification of MiMedx's Wound Powder Because Similar Products Were Devices](https://synopulse.com/a-court-vacated-the-fdas-biologic-classification-of-mimedxs-wound-powder-because-similar-products-were-devices/): The court did not rule on what AXIOFILL is. It ruled that FDA had not treated like wound care products alike.
- [Plaintiffs Say CMS' Frailty Rule Raises Projected Medicaid Losses From 6.4 Million to 8.2 Million a Year](https://synopulse.com/plaintiffs-say-cms-frailty-rule-raises-projected-medicaid-losses-from-6-4-million-to-8-2-million-a-year/): Congress named who is medically frail. CMS's rule decides who can prove it, and the new lawsuit is about that gap.
- [CMS Cancelled Coverage for 760,000 People and Froze New Brokers for 2027 Over Unauthorized Enrollments](https://synopulse.com/cms-cancelled-coverage-for-760000-people-and-froze-new-brokers-for-2027-over-unauthorized-enrollments/): CMS frames this as fraud recovery. Its release says much less about the 760,000 people whose marketplace coverage ends.
- [Medicare's Preliminary Lab Rates Cut Genomic Sequencing 23% and Proprietary Tests Just 2.4%](https://synopulse.com/medicares-preliminary-lab-rates-cut-genomic-sequencing-23-and-proprietary-tests-just-2-4/): The average cut is 16%. The tests carrying the newest science take the deepest cuts, and proprietary ones barely move.
- [Boehringer's $1 Billion Cancer Deal Will Pay to Put Envisagenics' ALS Drug Into the Clinic](https://synopulse.com/boehringers-1-billion-cancer-deal-will-pay-to-put-envisagenics-als-drug-into-the-clinic/): Boehringer is buying options on cancer targets. Envisagenics plans to spend the money taking an ALS drug into the clinic.
- [Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used](https://synopulse.com/beacon-succeeded-in-xlrp-where-biogen-and-jj-failed-on-an-endpoint-neither-of-them-used/): QuickCI read/Ophthalmology/Cell & Gene Tx Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used Athithi Verma· 22 September 2026· 2 min read· Synopulse Beacon Therapeutics said on 21 September 2026 that laru-zova met the FDA-endorsed primary endpoint of VISTA, a 12-month randomised trial in 85 males aged 12 to 48 with X-linked retinitis pigmentosa. A gain of at least 15 letters in low-light visual acuity was reached by 31.0% on the high dose (p=0.0019) and 24.1% on the low dose (p=0.0106), against none of the untreated controls. At least a 10-letter gain was reached ... Read more
- [Brazil Approved AstraZeneca's Camizestrant 17 Days After the FDA, Whose Own Advisers Had Voted Against It](https://synopulse.com/brazil-approved-astrazenecas-camizestrant-17-days-after-the-fda-whose-own-advisers-had-voted-against-it/): Every major regulator has now said yes to a strategy the FDA's advisers doubted. The constraint is a blood test.
- [Novartis's $900 Million BoomRay Licence Names No Target, No Isotope and No Upfront](https://synopulse.com/novartiss-900-million-boomray-licence-names-no-target-no-isotope-and-no-upfront/): Without an upfront, a target or an isotope, BoomRay's $900 million headline is a ceiling rather than a valuation.
- [Caplyta Doubled the Mania Response Rate, and Only Dry Mouth and Nausea Cleared J&J's Side Effect Bar](https://synopulse.com/caplyta-doubled-the-mania-response-rate-and-only-dry-mouth-and-nausea-cleared-jjs-side-effect-bar/): The efficacy is the headline. The competitive case sits in the side effect line, and it points at AbbVie's Vraylar.
- [A Custom ALS Drug Took Three Years to Build and One Year to Normalise One Man's Neurofilament](https://synopulse.com/a-custom-als-drug-took-three-years-to-build-and-one-year-to-normalise-one-mans-neurofilament/): Built in about three years for one mutation, it normalised a biomarker in one man. A larger cohort sits outside the paper.
- [UnitedHealthcare Is Enlisting Doctors Against the Paperwork Behind 43% of Projected Medicaid Losses](https://synopulse.com/unitedhealthcare-is-enlisting-doctors-against-the-paperwork-behind-43-of-projected-medicaid-losses/): CMS expects much of the coverage loss to come from process, not from failing the test. The insurer asked doctors to help.
- [China Ordered Rare Disease Clinics in Every Province by December and Left Payment Out](https://synopulse.com/china-ordered-rare-disease-clinics-in-every-province-by-december-and-left-payment-out/): Every instruction raises the number of diagnosed patients. None addresses what they can be prescribed, or who pays.
- [Merck Moved Every Japanese Keytruda Indication to a One-Minute Injection on a Single Lung Cancer Trial](https://synopulse.com/merck-moved-every-japanese-keytruda-indication-to-a-one-minute-injection-on-a-single-lung-cancer-trial/): One exposure trial in lung cancer carried every Japanese indication. The contest is now minutes and millilitres.
- [Telix Is Paying $1.65 Billion for ITM Without Handing the Sellers Any Cash at Closing](https://synopulse.com/telix-is-paying-1-65-billion-for-itm-without-handing-the-sellers-any-cash-at-closing/): The sellers receive shares, not cash, at closing, and $450m of the $700m earnout rests on a single year of sales.
- [India Got Three Different Access Mechanisms in Four Days](https://synopulse.com/india-got-three-different-access-mechanisms-in-four-days/): Three routes to patients in four days. In a market that pays out of pocket, not one announcement carries a price.
- [Japan Clears Five Products in a Day, Two With a Price Cut Attached](https://synopulse.com/japan-clears-five-products-in-a-day-two-with-a-price-cut-attached/): Five approvals, one calendar date, one November pricing round. The two expansions are the ones the system taxes.
- [The CHMP Refused Nothing in September and Five Applications Were Pulled Anyway](https://synopulse.com/the-chmp-refused-nothing-in-september-and-five-applications-were-pulled-anyway/): Twelve approvals and no refusals. Apitegromab was cleared in the US on 11 September and pulled in Europe by the 17th.
- [Lilly's New Combination Beats its Own Monotherapy](https://synopulse.com/lillys-new-combination-beats-its-own-monotherapy/): Median PFS doubled to 11.1 months against Inluriyo alone. The comparison payers will run is not in the package.
- [GENEROUS Signings Jump From Seven to 40 States in a Week](https://synopulse.com/generous-signings-jump-from-seven-to-40-states-in-a-week/): Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.
- [Korea Repriced 36 Fewer Items This Year and Took Out the Same ₩33.9 Billion](https://synopulse.com/korea-repriced-36-fewer-items-this-year-and-took-out-the-same-%e2%82%a933-9-billion/): Thirty-six fewer items produced the same saving. Nothing about efficacy changed. The medicines that grew paid for it.
- [OrphanPulse Wk 38: Two Untreatable Childhood Diseases Got First Therapies in 24 Hours](https://synopulse.com/orphanpulse-wk-38-two-untreatable-childhood-diseases-got-first-therapies-in-24-hours/): Seventeen treated children carried a gene therapy to standard full approval. Effect size did the work design could not.
- [NeuroPulse Wk 38: Xenon Filed in Epilepsy and Paused in Psychiatry on the Same Day](https://synopulse.com/neuropulse-wk-38-xenon-filed-in-epilepsy-and-paused-in-psychiatry-on-the-same-day/): The NDA and the enrolment pause went out in one release. Xenon says the events match the mechanism, not the indication.
- [Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology](https://synopulse.com/rare-disease-produced-two-first-ever-approvals-in-two-days-and-both-of-them-are-neurology/): The FDA approved first-ever treatments for Sanfilippo syndrome type A and ataxia-telangiectasia a day apart. Both diseases destroy the nervous system.
- [Roche Paid $36.5 Million to Screen 300,000 Bispecific Combinations](https://synopulse.com/roche-paid-36-5-million-to-screen-300000-bispecific-combinations/): Roche has not bought a molecule or a target. It has bought a search, and the pairing is an output rather than an input.
- [Novo's $1.4 Billion Orbis Deal Does Not Say What It Paid at Signing](https://synopulse.com/novos-1-4-billion-orbis-deal-does-not-say-what-it-paid-at-signing/): The headline has no denominator. Upfront and milestones are stated as one number, which makes the commitment impossible to assess.
- [NICE Wants Cosmetic Providers to Screen for BDD and Refer Rather Than Operate](https://synopulse.com/nice-wants-cosmetic-providers-to-screen-for-bdd-and-refer-rather-than-operate/): Coverage will call this a mental health guideline. One recommendation reaches into a commercial market and tells its providers to turn business away.
- [ICER Priced Tavapadon Before the FDA Approved It or AbbVie Named a Price](https://synopulse.com/icer-priced-tavapadon-before-the-fda-approved-it-or-abbvie-named-a-price/): An assessment body has priced a drug that has neither an approval nor a price. The number will sit in every payer negotiation that follows.
- [NICE Reversed on Enhertu Because the Threshold Moved, Not the Evidence](https://synopulse.com/nice-reversed-on-enhertu-because-the-threshold-moved-not-the-evidence/): The clinical evidence did not change. NICE's cost-effectiveness threshold did, as a term of a bilateral trade agreement.
- [GENEROUS Lets Manufacturers Cut Medicaid Prices Without Touching Best Price or 340B](https://synopulse.com/generous-lets-manufacturers-cut-medicaid-prices-without-touching-best-price-or-340b/): Seven of 19 applicant states have signed. CMS itself tells them to check whether its international price beats the rebates they already have.
- [Korea's Reimbursement Delay Is a Staffing Problem, and the Ministry Said So](https://synopulse.com/koreas-reimbursement-delay-is-a-staffing-problem-and-the-ministry-said-so/): An industry association found the public agrees with industry. The news came later, from a division director naming headcount as the bottleneck.
- [The First Approval for Denecimig Came From Riyadh, Not Washington](https://synopulse.com/the-first-approval-for-denecimig-came-from-riyadh-not-washington/): One of the four Phase 3 studies is a safety-only switch from emicizumab. The commercial target was the incumbent, not the untreated.
- [ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC](https://synopulse.com/adcs-returned-0-46-in-relapsed-disease-and-1-15-in-the-front-line-at-wclc/): The dividing line is not the target or the payload. It is the setting: relapsed disease against chemotherapy, or the front line against chemo-IO.
- [Axon Targeting's Switch Lives in the Cell Body Observed Here, Not Operated](https://synopulse.com/axon-targetings-switch-lives-in-the-cell-body-observed-here-not-operated/): Regeneration programmes can make axons grow. If targeting is transcriptional, growth was always the achievable half of a two-part problem.
- [NICE Withdrew Four Appraisals Because the Medicine Went Off Patent. ](https://synopulse.com/nice-withdrew-four-appraisals-because-the-medicine-went-off-patent/): Going off patent now costs a medicine its named appraisal. And the withdrawal is a routing decision carrying no right of appeal.
- [CMS Added Five Tracks to ACCESS. The Payer Pledge Covers 165 Million People Who Cannot Join It.](https://synopulse.com/cms-added-five-tracks-to-access-the-payer-pledge-covers-165-million-people-who-cannot-join-it/): The expansion is the announcement. Payers covering 165 million pledged to align with a model none of their members can join.
- [Radiopharmaceuticals: sixteen years of deal data on where the field goes next](https://synopulse.com/radiopharmaceuticals-sixteen-years-of-deal-data-on-where-the-field-goes-next/): Buyers have concluded that radiopharmaceuticals are a platform business, and they are paying platform prices.
- [The UK Commission Wants L-Plates for AI and an End to One-Time Approval](https://synopulse.com/the-uk-commission-wants-l-plates-for-ai-and-an-end-to-one-time-approval/): Coverage is calling these new AI rules. What they propose is replacing the single approval decision with supervised entry and permanent monitoring.
- [Lilly Confirmed the Calculations Were Wrong. A Jury Is Deciding What That Cost Nektar.](https://synopulse.com/lilly-confirmed-the-calculations-were-wrong-a-jury-is-deciding-what-that-cost-nektar/): Most partnership disputes turn on what data meant. Both sides here accept the published numbers were wrong, and every correction favours the drug.
- [Years After NCCN Recommended It, FET-PET Finally Has an FDA-Approved Drug](https://synopulse.com/years-after-nccn-recommended-it-fet-pet-finally-has-an-fda-approved-drug/): The clinical case was settled before the regulatory one. Clinicians held an NCCN recommendation with no lawful product to act on it.
- [Behind the Headlines: How the Leaders Really Performed](https://synopulse.com/behind-the-headlines-how-the-leaders-really-performed/): Read together rather than one at a time, the quarter divides along four lines, and none of them is visible in a headline growth rate.
- [Korea adds Pergoveris pen to reimbursement rolls, vial already covered](https://synopulse.com/korea-adds-pergoveris-pen-to-reimbursement-rolls-vial-already-covered/): This is a device listing, not an eligibility expansion. The indication is unchanged, and the criteria were relaxed back in April 2025.
- [CDA-AMC reverses course, backs Leqembi's first ruling content still undisclosed](https://synopulse.com/cda-amc-reverses-course-backs-leqembis-first-ruling-content-still-undisclosed/): Four words carry the news: follows a reconsideration. CDA-AMC reached a different conclusion first, and neither release says what it was.
- [Nine More Drugmakers Signed MFN Deals. The Coalition Formed to Fight Them Did Not.](https://synopulse.com/nine-more-drugmakers-signed-mfn-deals-the-coalition-formed-to-fight-them-did-not/): The useful information is who is absent. The mid-sized biotech coalition formed to contest MFN has no member among the nine signatories.
- [Korea Runs Three Reimbursement Speeds. September Shows All Three at Once.](https://synopulse.com/korea-runs-three-reimbursement-speeds-september-shows-all-three-at-once/): The lane determines the timeline, and it is set long before you file. Model the Korean queue, not the approval date.
- [3 of 1,357 Cleared AI Devices Have Public Outcome Trials. The Study Has No Non-AI Comparator.](https://synopulse.com/3-of-1357-cleared-ai-devices-have-public-outcome-trials-the-study-has-no-non-ai-comparator/): The census counts publicly registered evidence, so it measures disclosure. Without a non-AI comparator it cannot show this is an AI problem.
- [Biocon Makes It, a Consultancy Holds the Licence, and Sandoz Sells It](https://synopulse.com/biocon-makes-it-a-consultancy-holds-the-licence-and-sandoz-sells-it/): Three parties, three functions, and Biocon holds only the middle one. Treat the caretaker MAH structure as the Japanese default, not the exception.
- [Abbott Cleared the First Dual Glucose and Ketone Sensor. FDA Judged Accuracy, Not Admissions.](https://synopulse.com/abbott-cleared-the-first-dual-glucose-and-ketone-sensor-fda-judged-accuracy-not-admissions/): The label says diabetes. The clinical argument is type 1. Coverage conversations start from 2.1 million people, not 40.1 million.
- [This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal.](https://synopulse.com/this-money-buys-equipment-not-operations-your-2031-answer-decides-the-2027-deal/): Half the pot is split equally, so award size is a weak proxy for market size. Your buyer is a state rural health office, not a hospital.
- [Three Proteins Flip the Tumour Sphere. Blocking Two of Them Flips It Back Toward Chemo-Resistance.](https://synopulse.com/three-proteins-flip-the-tumour-sphere-blocking-two-of-them-flips-it-back-toward-chemo-resistance/): Blocking HER2 and HER3 impaired attachment, but pushed spheres into the state the same paper describes as chemo-resistant and pro-migratory.
- [Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing](https://synopulse.com/evernorth-adopts-locus-in-three-states-and-states-that-the-review-process-is-not-changing/): Three statutes across five years, discharged on one date. Evernorth says only the source of criteria changes, not the review process itself.
- [A Jury Convicted the Philips Engineer. The Approach Came as His Plant Was Closing.](https://synopulse.com/a-jury-convicted-the-philips-engineer-the-approach-came-as-his-plant-was-closing/): The approach came in 2017 as Philips prepared to close the plant. A site closure is a knowledge event before it is a cost event.
- [DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes](https://synopulse.com/doj-settled-with-the-in-home-vendor-not-the-health-plan-over-four-medicare-advantage-codes/): DOJ did not settle with a health plan. It settled with the in-home vendor that supplied the codes, and named the risk-share contract as the incentive.
- [Teva Faces New Probe in Turkey Over Conduct Flagged by EU](https://synopulse.com/turkeys-teva-investigation-names-the-same-two-conducts-the-eu-fined-it-e462-6-million-for/): Not a new theory of harm. It is the European Commission's Copaxone decision run a second time, with two of the same corporate entities named.
- [Japan Approved Orladeyo for Under-Twelves in an Open-Label Interim Analysis of 29 Children](https://synopulse.com/japan-approved-orladeyo-for-under-twelves-in-an-open-label-interim-analysis-of-29-children/): The molecule has been approved in Japan since 2021. What is new is a formulation a two-year-old can swallow, and that is the commercial move.
- [A Dual MYC and GSPT1 Degrader Extended Survival by Over 300% in One Preclinical Model](https://synopulse.com/a-dual-myc-and-gspt1-degrader-extended-survival-by-over-300-in-one-preclinical-model/): The loop is the discovery, not the degrader. If GSPT1 supports MYC translation, a GSPT1-only degrader should permit MYC to recover.
- [China Will Pay One Price for 158 Conditions, Whatever the Hospital](https://synopulse.com/china-will-pay-one-price-for-158-conditions-whatever-the-hospital/): Same disease, same payment across tiers. Of 31 DRG categories, 27 are internal medicine, where drug cost rather than theatre time drives the case.
- [France Funded Two Cancer Drugs the Same Week. One Was Rated Therapeutic Progress, One Was Not.](https://synopulse.com/france-funded-two-cancer-drugs-the-same-week-one-was-rated-therapeutic-progress-one-was-not/): Listing is granted by indication, not by licence. Columvi is funded for one situation and refused for the rest of its authorisation.
- [Avulux Won a De Novo and Created the Category Its Competitors Will File Into](https://synopulse.com/avulux-won-a-de-novo-and-created-the-category-its-competitors-will-file-into/): Going first through a De Novo builds the road behind you. Avulux owns the claim today and has created the category rivals will file 510(k)s into.
- [ASCO's First ctDNA Guideline Found Few Instances of Clinical Utility. Residual Disease Got No Recommendation at All.](https://synopulse.com/ascos-first-ctdna-guideline-found-few-instances-of-clinical-utility-residual-disease-got-no-recommendation-at-all/): Most of the guideline concerns where ctDNA should not be used. The application carrying the largest commercial expectations got no recommendation.
- [RK-251 Was Tested Against One Cancer Cell Line. The Problem It Was Built to Solve Is Bioavailability.](https://synopulse.com/rk-251-was-tested-against-one-cancer-cell-line-the-problem-it-was-built-to-solve-is-bioavailability/): FindingsScience read/Oncology/Small Molecule RK-251 Was Tested Against One Cancer Cell Line. The Problem It Was Built to Solve Is Bioavailability. Athithi Verma· 25 August 2026· 2 min read· Synopulse What they did A research article in the Journal of Medicinal Chemistry, published 23 July 2026 across pages 17342 to 17365. Kesarwani and colleagues at IIT Guwahati and IASST built RK-251, a reactive oxygen species responsive prodrug of NBDHEX, by coupling the inhibitor to a dual positively charged near-infrared fluorophore, QCy7, and a ROS-responsive unit. They characterised activation in aqueous medium, tested anticancer activity in MDA-MB-231 triple-negative breast cancer cells against non-malignant ... Read more
- [Roche Cleared an Alzheimer's Blood Test With Three Result Categories. The Middle One Is Where PET Survives.](https://synopulse.com/roche-cleared-an-alzheimers-blood-test-with-three-result-categories-the-middle-one-is-where-pet-survives/): A three-way result means some patients resolve neither way, and those still go to imaging. Roche has not said how many land in the middle.
- [Trodelvy Now Covers First-Line TNBC Across PD-L1 Status. The Two Regimens Are Not Equally Tolerated.](https://synopulse.com/trodelvy-now-covers-first-line-tnbc-across-pd-l1-status-the-two-regimens-are-not-equally-tolerated/): Serious adverse reactions ran at 38% in the combination trial against 26% in the monotherapy trial. Same drug, same line, different companion.
- [Rett Syndrome Gets Its First EU Treatment. Thirty Pricing Negotiations Start Now.](https://synopulse.com/rett-syndrome-gets-its-first-eu-treatment-thirty-pricing-negotiations-start-now/): First and only is not the same as available. One authorisation covers 30 jurisdictions, each of which now prices the drug separately.
- [NICE Backed a Weekly Insulin Before It Has a Licence, Then Told Prescribers to Pick the Cheapest Option](https://synopulse.com/nice-backed-a-weekly-insulin-before-it-has-a-licence-then-told-prescribers-to-pick-the-cheapest-option/): QuickAccess read/Endocrine & Metabolic/Peptide NICE Backed a Weekly Insulin Before It Has a Licence, Then Told Prescribers to Pick the Cheapest Option Athithi Verma· 25 August 2026· 2 min read· Synopulse NICE published final draft guidance recommending insulin efsitora alfa (Onswik), from Eli Lilly, for adults with type 2 diabetes. Given once weekly by pre-filled subcutaneous pen, it would cut annual injections from 365 to 52 for someone switching from a daily basal regimen, a reduction of 313 injections. The recommendation is conditional on the MHRA licensing the product, which has not happened. An appeal period is open and, barring appeals, ... Read more
- [Roche Paid $190 Million Up Front on a $2.3 Billion Headline for a Phase 1 Obesity Asset](https://synopulse.com/roche-paid-190-million-up-front-on-a-2-3-billion-headline-for-a-phase-1-obesity-asset/): https://synopulse.com/wp-content/uploads/2026/08/Roche-Paid-190-Million-Up-Front-on-a-2.3-Billion-Headline-for-a-Phase-1-Obesity-Asset.webp
- [FDA Moved a Class of Cancer Tests From PMA to 510(k). Fewer Than Five Parties Commented.](https://synopulse.com/fda-moved-a-class-of-cancer-tests-from-pma-to-510k-fewer-than-five-parties-commented/): The order moves these tests from PMA to 510(k). One special control was deleted, and the predicate chain is where the change compounds.
- [Canada Moved Two Cancer Drugs Forward in One Week. Neither Went the Normal Route.](https://synopulse.com/canada-moved-two-cancer-drugs-forward-in-one-week-neither-went-the-normal-route/): One drug reached review only because payers filed for a manufacturer that had not. The other was recommended on evidence the committee called inconclusive.
- [In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part](https://synopulse.com/in-ustekinumab-biosimilars-approval-stopped-being-the-hard-part/): A biosimilar licence used to be the scarce asset. In ustekinumab it is the entry ticket, and the returns go to whoever solves supply and device.
- [The Number Everyone Will Quote About European Launches Rests on Eleven Products](https://synopulse.com/the-number-everyone-will-quote-about-european-launches-rests-on-eleven-products/): The 22.9% figure driving coverage of European launch delays is 48 products falling to 37. The pricing finding underneath it is stronger and barely quoted.
- [Singapore Approved Both Blenrep Combinations. Korea Reimbursed Only the One With Survival Data.](https://synopulse.com/singapore-approved-both-blenrep-combinations-korea-reimbursed-only-the-one-with-survival-data/): Same drug, same week, two Asian markets. The regulator approved on progression-free survival. The payer funded only the regimen with overall survival data.
- [A KAIST Barrier Chip Separated Three Glioblastoma Patients That MGMT Testing Called Identical](https://synopulse.com/a-kaist-barrier-chip-separated-three-glioblastoma-patients-that-mgmt-testing-called-identical/): Three glioblastoma patients returned identical MGMT results and behaved differently on a barrier chip. The sample size is three, and the framing still matters.
- [Two FDA Device Authorisations, Two Sets of Evidence Narrower Than the Headline](https://synopulse.com/two-fda-device-authorisations-two-sets-of-evidence-narrower-than-the-headline/): Aletta matches human phlebotomists only when it agrees to attempt a draw. Narwhal cleared on bench and animal data, citing a trial with a different probe.
- [Two First-Ever Rare Disease Approvals Landed the Same Day. Both Were Measured by Proxy.](https://synopulse.com/two-first-ever-rare-disease-approvals-landed-the-same-day-both-were-measured-by-proxy/): Pasatru's flare benefit is clinician-assessed only. GENGLYCOS is indicated to reduce cornstarch intake. Two firsts, both measured a step from the patient.
- [A UC Irvine Team Names Five Mitochondrial Drug Classes for CAR-T Neurotoxicity and Says Nobody Is Testing Any of Them](https://synopulse.com/a-uc-irvine-team-names-five-mitochondrial-drug-classes-for-car-t-neurotoxicity-and-says-nobody-is-testing-any-of-them/): Five mitochondrial drug classes named for CAR-T neurotoxicity, and the authors say none is under formal investigation. Every one is generic or preclinical.
- [Everyone's New Pharma Lane Runs Through Heathrow](https://synopulse.com/everyones-new-pharma-lane-runs-through-heathrow/): Two carriers built new pharma lanes in five weeks. Both end at Heathrow, an airport that lost a day to one transformer fire in March 2025.
- [MHRA Puts Microbiome Medicines Inside the Existing Framework While the EU Builds a Separate One](https://synopulse.com/mhra-puts-microbiome-medicines-inside-the-existing-framework-while-the-eu-builds-a-separate-one/): No bespoke regime is coming. Microbiome medicines meet the standard biological bar in the UK, while the EU builds a separate SoHO framework.
- [PDUFA VIII Keeps Every Review Clock and Hires Four Auditors](https://synopulse.com/pdufa-viii-keeps-every-review-clock-and-hires-four-auditors/): Industry renegotiated what it pays FDA without changing what it gets. The clocks held. What expanded is the apparatus for verifying the money buys reviewers.
- [The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers](https://synopulse.com/the-first-phase-3-win-for-an-mrna-cancer-therapy-arrives-without-its-numbers/): The first Phase 3 win for an mRNA cancer therapy. Statistical significance was reported, effect size was not, and overall survival is still open.
- [Four Health Systems Automated the Prior Authorization Question, Not the Answer](https://synopulse.com/four-health-systems-automated-the-prior-authorization-question-not-the-answer/): The piece of the federal prior authorization mandate that shipped five months early is the piece that cannot deny anything.
- [Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It](https://synopulse.com/novartis-declines-canadian-reimbursement-for-vanrafia-five-weeks-after-health-canada-approved-it/): Health Canada cleared Vanrafia on a Week 36 proteinuria readout. Novartis will not take that same package into Canadian pricing review.
- [CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route](https://synopulse.com/cms-comments-close-on-a-rule-that-retires-the-small-biotech-exemption-and-shuts-the-hyaluronidase-route/): QuickAccess read/Oncology/Antibody CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route Athithi Verma· 19 August 2026· 2 min read· Synopulse The 60-day comment period on CMS-4215-P closed at 5pm on 17 August 2026. The proposed rule, published in the Federal Register on 16 June 2026, would codify the Medicare Drug Price Negotiation Program for initial price applicability year 2029 and beyond, replacing the program instruction authority that expires after 2028. The Small Biotech exception from being a negotiation-eligible drug applied only to IPAY 2026, 2027 and 2028, so CMS did not propose to ... Read more
- [A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold.](https://synopulse.com/a-third-centiloid-scale-just-cleared-the-first-two-already-disagree-at-the-threshold/): Cortechs.ai clears NeuroQuant PET for Centiloid amyloid quantification, entering a field where the two incumbent scales differ by more than 10 Centiloids.
- [OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later](https://synopulse.com/orphanpulse-wk-33-the-competitor-got-a-pdufa-date-five-days-later/): Five days after Tarsus paid $450 million for a Stargardt asset reading out in 2029, the competitor got a PDUFA date of 12 February 2027.
- [NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard](https://synopulse.com/neuropulse-wk-33-jazz-bet-820m-on-a-new-fda-evidence-standard/): Jazz committed $820 million at signing for an epilepsy drug with one early trial behind it. The justification is a regulatory pathway, not the data.
- [ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC](https://synopulse.com/vignet-reported-82-55-discrimination-predicting-immunotherapy-response-in-nsclc/): Findings Science read / Oncology / AI & ML ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC Athithi Verma · 18 August 2026 · 3 min read · Synopulse A Hong Kong Polytechnic University team reports that a network fusing whole slide pathology images with gene expression data reached 82.55% discrimination in classifying which non-small cell lung cancer patients respond to immunotherapy. The same announcement introduces a separate digital twin platform now entering commercialisation. The two arrived together and read as one thing. Only one has a published number attached. What they did Multimodal deep learning study. ViGNet, the Visual-Global ... Read more
- [Payers Do Not Cover Wellness. In Women's Health, That Is a Naming Decision.](https://synopulse.com/payers-do-not-cover-wellness-in-womens-health-that-is-a-naming-decision/): The sharpest advice in the roadmap is about vocabulary. Payers will not fund wellness, and in women's health that classification is partly a choice.
- [The FDA Approved a Device and a Sentence. The Sentence Is About Other Molecules.](https://synopulse.com/the-fda-approved-a-device-and-a-sentence-the-sentence-is-about-other-molecules/): The label credits outcomes trials run on statins and monoclonal antibody PCSK9 inhibitors. LEROCHOL is neither, and has no outcomes trial of its own.
- [One Missed, One Published the Arm That Failed, One Disclosed a Verb](https://synopulse.com/one-missed-one-published-the-arm-that-failed-one-disclosed-a-verb/): Three Phase 3 toplines in one day, and the detail released runs inversely to the strength of the result. One company disclosed no number at all.
- [DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week](https://synopulse.com/dealpulse-signal-wk-33-rare-disease-took-two-thirds-of-the-week/): Jazz paid $820 million for a Phase 1b asset. PTC paid $111 million for a filed one. The difference was not clinical risk, it was seller leverage.
- [Two TROP2 Conjugates Reached the Same Patients Ten Weeks Apart, and Payers Finally Have a Choice to Make](https://synopulse.com/two-trop2-conjugates-reached-the-same-patients-ten-weeks-apart-and-payers-finally-have-a-choice-to-make/): Until this summer every approved ADC held its indication alone. Two TROP2 conjugates now share one first-line population, and payers finally have a comparator.
- [CMS Projects: Fewer Losses and Bigger Savings. That Only Works If the Sick Are Removed.](https://synopulse.com/cms-projects-fewer-losses-and-bigger-savings-that-only-works-if-the-sick-are-removed/): CMS forecasts fewer disenrollments than CBO and higher savings. Both hold only if the people removed are the expensive ones, which means the sick.
- [Two Dominican High-Cost Lists Overlap by Only 44 Products. FOMAC Would Be a Third.](https://synopulse.com/two-dominican-high-cost-lists-overlap-by-only-44-products-fomac-would-be-a-third/): The country already covers this. Two schemes list 120 and 115 high-cost medicines, overlapping by 44. FOMAC would be a third list, starting at 13.
- [The Effect Size Is 0.81. The Number That Decides the Business Is 6.4 Hours.](https://synopulse.com/the-effect-size-is-0-81-the-number-that-decides-the-business-is-6-4-hours/): Effect size 0.81 settles the efficacy question. The number that decides the business is 6.4 hours of supervised monitoring per dose.
- [Lilly Can Sue the Sellers. It Can Only Ask the Payment Networks.](https://synopulse.com/lilly-can-sue-the-sellers-it-can-only-ask-the-payment-networks/): Six suits against small peptide sellers is not a strategy for a market spanning a hundred countries. It is a demonstration attached to an appeal.
- [In Japan, Expanding a Label Is What Triggers the Price Cut](https://synopulse.com/in-japan-expanding-a-label-is-what-triggers-the-price-cut/): Dupixent, Nucala and Vyvdura were all cut after adding an indication. In Japan the trigger for a price cut is the drug reaching more patients.

## Pages

- [Home](https://synopulse.com/): The Beats Analysis Coverage
- [Terms of Service](https://synopulse.com/terms-of-service/): Last updated: November 2025 Welcome to Synopulse (“we,” “our,” “us”). These Terms of Service (“Terms”) govern your use of https://synopulse.com, our articles, reports, and any related digital products or services. By accessing or using Synopulse, you agree to be bound by these Terms and our Privacy Policy.If you do not agree with any part of these Terms, please discontinue use of our website immediately. 1. About Synopulse Synopulse is a digital media platform focused on pharmaceutical innovation, market access, and health technology assessment (HTA).We provide curated news, analytical reports, and insights for professionals in healthcare, biotechnology, and policy. 2. Acceptance of ... Read more
- [Privacy Policy](https://synopulse.com/privacy-policy/): Privacy Policy Last updated: November 2025 Synopulse (“we,” “our,” “us”) operates https://synopulse.com, an independent media platform providing news, insights, and reports focused on pharmaceutical innovation, health technology assessment (HTA), and market access strategy. This Privacy Policy describes how we collect, use, and protect your personal information when you visit our website, subscribe to our newsletters, or interact with our content. By using our website, you agree to this Privacy Policy and our Terms of Service. 1. Information We Collect We collect both personal and non-personal data to provide a better user experience and comply with our legal obligations. 1.1 Personal Information ... Read more
- [About US](https://synopulse.com/company/): Synopulse is an independent, fast-growing platform dedicated to delivering clear, analytical, and timely insights across biopharmaceuticals, market access, MedTech, regulatory strategy, evidence development, and healthcare innovation. Our mission is simple: help industry professionals, analysts, and decision-makers stay ahead of what is shaping global healthcare markets. The healthcare landscape moves at extraordinary speed. Each day brings new clinical data, payer decisions, policy shifts, mergers, trial milestones, and technologies that reshape patient care and commercial strategy. Synopulse was created to cut through the noise and translate complexity into clarity. We focus on structured, factual, and unbiased reporting so readers can understand not only ... Read more

## Optional

- [Agent (MCP protocol)](websites-agents.hostinger.com/synopulse.com/mcp)

[comment]: # (Generated by Hostinger Tools Plugin)